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 This dissertation provides an in-depth analysis of the evaluation of the Menopause-
Specific Quality of Life (MENQOL) Questionnaire, a tool used by clinicians to understand 
women’s symptomatology as they progress through the menopausal transition.  While the 
MENQOL was rigorously developed through various methods, a factor analysis had never 
been conducted on the instrument.  A factor analysis was conducted on this tool, using the 
existing version, and again with the existing version and additional vaginal health items.  
Results showed that the items in the instrument largely held to the domains under which 
they were intended.  When the vaginal health items were added, a new domain of vaginal 
health items emerged.  
 There currently exists little literature which examines the explicit association between 
vasomotor and psychosocial symptoms among postmenopausal women.  An additional aim 
of this dissertation was to examine this association using a longitudinal population-based 
study of postmenopausal women in the United States.  Results showed that there was a 
small, statistically significant association between an increase in vasomotor symptoms and 
an increase in psychosocial symptoms. 
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CHAPTER I 
 STATEMENT OF SPECIFIC AIMS 
 
 The quality of life among menopausal women has become an increasingly hot 
topic in recent medical and sociological research.  Specifically, vasomotor and 
psychological symptoms remain at the forefront of common, bothersome symptoms 
which affect a woman’s quality of life.  As many as 95% of menopausal women may 
exhibit vasomotor symptoms, which may frequently disrupt work, sleep and other 
activities.  Furthermore, psychological symptoms such as depression are common in as 
many as 60% of women going through the menopausal transition.  The high prevalence 
of these two common and bothersome conditions make it important that more studies be 
conducted to explore the degree to which these symptoms are interrelated.  Several 
instruments have been designed to evaluate the quality of life among menopausal 
women.  However, many of these instruments are used in small clinic populations, and 
have not yet been evaluated for psychometric properties within a population-based 
sample.  
 
The specific aims of this dissertation are: 
1) Evaluate and Revise the Menopause-Specific Quality of Life (MENQOL) 
Questionnaire.   
 A.  Evaluate the efficiency of items in the original MENQOL instrument in a  
                  population-based sample. 
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 Rationale:  The MENQOL instrument domains have never been evaluated in a 
population-based study.  When used in a population-based sample, there may be symptoms 
that load differently than originally assigned when the MENQOL was developed.  Some 
symptoms may not load well into any of the domains and other symptoms may load into 
different domains than their original assignment. 
 
 B.  Evaluate the contribution of six candidate items on vaginal health to the  
                 original MENQOL instrument. 
Rationale:  The original MENQOL contained one vaginal symptom, “Vaginal dryness 
during intercourse”, that was part of the “Sexual” domain.  Six additional vaginal symptoms 
were appended to the end of the MENQOL in the Menopause Epidemiology (MEPI) Study to 
gather information on presence and amount of bother for these symptoms.  Given that 
vaginal symptoms are physical in nature, but have sexual implications, these symptoms 
divided into both physical and sexual vaginal health domains.   
The MENQOL instrument has been used as an outcome tool in clinic populations to 
demonstrate the impact of an intervention on quality of life.  Yet, it had not been factor-
analyzed in a population-based sample and many vaginal symptoms were not included.  
The objective of these analyses is to make the MENQOL more efficient through the use of 
factor analysis.  We used these aims to help address the current limitations of the MENQOL 
and intended to make it as accurate, efficient and as meaningful as possible through the 
analyses described herein.  
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2) Evaluation of the Relationship between Vasomotor Symptoms and Psychosocial 
Symptoms over time.   Is an increase in bothersome vasomotor symptoms over time 
associated with an increase in bothersome psychosocial symptoms over time?   
 Rationale: Other studies have looked at the relationship between vasomotor and 
psychological symptoms, yet no literature reports on the relationship between the two with 
respect to the degree of bother it causes the woman. 
  
 These aims were met via the use of the Menopause Epidemiology (MEPI) study.  
The MEPI Study was a population-based, cross-sectional study conducted in 2005 among a 
randomly selected group of 4,402 pre-, peri-, and post-menopausal women in the United 
States.  These women were followed over time to 2007 and given another survey, providing 
longitudinal information.  This study examined the prevalence and predictors of menopausal 
symptoms, and included several questions on the frequency, duration, severity, and degree 
of bother from hot flashes.  Additionally, the MEPI questionnaires included the Menopause–
Specific Quality of Life (MENQOL) Questionnaire, which provided the ability to conduct 
factor analysis on a population-based sample of women.  The MEPI follow-up survey, 
conducted among the same women in 2007, enrolled 1,626 women aged 42-67 years who 
participated in the MEPI study to assess menopausal symptoms.  I utilized the Menopause 
Epidemiology Study cohort and the follow-up to determine whether there was an association 
between bothersome hot flash and depressive symptoms, using the MENQOL, which 
contained both a vasomotor and psychosocial domain.  
 The contribution that this research could have on both healthcare providers and 
menopausal women is profound.  The evaluation of the existing MENQOL instrument can 
allow researchers to remove items which were not be pertinent to a woman’s quality of life, 
thus reducing the time and burden on the respondent filling out the instrument.  Additionally, 
vaginal symptoms are also bothersome to menopausal women, so the potential inclusion of 
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these items to an existing QOL instrument may prove to be beneficial to a physician working 
with a menopausal woman to find the best treatment.  Finally, the evaluation of both 
vasomotor and psychosocial symptoms leads to better understanding of the overlap of these 
conditions and may lead to better treatment practices and improved therapies for the future.
CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
A.  Introduction and Background 
 
 A woman transitioning through midlife may be experiencing many adjustments 
with family and work life and bothersome menopausal symptoms may only add to this 
burden and discomfort.  During this transitory period, it is important to identify and 
counteract these bothersome symptoms where possible, through traditional medications 
or alternative medicine.  Reducing the degree of bother from menopausal symptoms 
may greatly enhance the quality of life of the menopausal woman. 
 Quality of life of menopausal women has been the subject of controversial 
literature for a number of years and various instruments have been developed in an 
effort to define and quantify these symptoms (1).  Menopause is defined as the day that 
is one year (365 days) after the last menstrual period.  The time after this point is termed 
post-menopause.  The menopausal transition is defined by the period of time prior to 
menopause when there is a gradual loss of estrogen after decreasing periods of 
ovulation.  Symptoms that may accompany menopause include hot flashes, night 
sweats, depression and other mood disorders, vaginal atrophy, female sexual 
dysfunction, changes in skin (tone, appearance and elasticity) and weight gain.  These 
symptoms may impact work, family life, and social settings.  The objectives of this 
dissertation are to evaluate 1) the psychometric properties of the Menopause-Specific 
Quality of Life Questionnaire and 2) the association between bothersome hot flashes 
and depression. 
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The Menopause-Specific Quality of Life Questionnaire 
 The Menopause-Specific Quality of Life Questionnaire (MENQOL) was 
developed in 1996 as an instrument to measure menopausal symptoms and their 
associated degree of bother (2).  Item formulation was based on existing literature, items 
on existing questionnaires on menopause-related quality of life, and the clinical 
experience of the investigators.  Additional items were based on focus group discussion 
with eight women.  This resulted in 106 symptoms generated by input from researchers 
and post-menopausal women. 
 To begin item reduction, 88 women were recruited from clinics via mailed 
questionnaires, newspaper articles and advertisements, and word-of-mouth.  Eligible 
women were between the ages of 42 and 67 years, were two to seven years 
postmenopause, had not used hormone therapy in the previous six months and had an 
intact uterus.  The participants were asked to rate whether or not they had experienced 
the symptom in the past month.  If the answer was yes, then they were asked to rate the 
degree to which that symptom was bothersome on a 7-point Likert scale.  The scale 
ranged from 0 (not at all bothered) to 6 (extremely bothered).    
 
Development and Psychometric Properties of the MENQOL 
 The development of the MENQOL included designing the individual symptoms, 
and defining and scoring four domains based on these items.  The authors of the 
MENQOL calculated importance scores for each item by multiplying the frequency that 
the symptom was reported and the mean bothersome score for that item for each of the 
88 postmenopausal women that had taken the initial questionnaire.  Each question was 
assigned to a domain which most closely represented a specific construct based on the 
authors’ clinical experience.  Four domains were created: vasomotor, psychosocial, 
physical and sexual.  Items were ranked by importance scores and were removed if the 
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importance scores were too low (no threshold was given in the paper).  Exceptions to 
this general rule were items that frequently appeared in the participants’ responses but 
were not necessarily bothersome; these items remained in the questionnaire.  There 
were several items in the sleep disturbances and joint and muscle aches that were 
redundant, so the item with the highest importance score was selected to avoid 
redundancy.  The top three items in each domain, based on the importance scores 
remained in the questionnaire.  The rest of the items were ranked by importance score 
from high to low and were added to the appropriate domains, resulting in the MENQOL 
contained 29 items.  
 Several different properties of the MENQOL were measured to determine validity 
and reliability.  Face validity of the test was determined by asking a separate set of 
postmenopausal women if they felt the questionnaire assessed the intended concepts.  
Content validity to determine the importance of the items was assessed using ten 
experts in the field of menopause and quality of life.  In order to determine construct 
validity, each domain was validated against an existing questionnaire which measured 
similar items.  The vasomotor, physical, and psychosocial domains were validated using 
the somatic, psychosomatic and psychosocial subscales of the Neugarten and Kraines’ 
Menopausal Symptom checklist (2).  Discriminant validity was good in each of these 
cases, indicating that those who were not experiencing the problem would not be likely 
to select it (p<0.001).  The psychosocial domain of the MENQOL was also validated 
against the General Well-Being Schedule (3).  The sexual domain of the MENQOL was 
validated against Channon and Balinger’s Vaginal Symptoms Score, also with good 
discriminant validity (2).   
 Test-retest reliability was measured via intraclass correlation coefficients and 
Pearson correlations.  Intraclass correlation coefficients showed good stability over time 
for all domains except the Vasomotor domain, which the authors argue is an artifact of 
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the changing hot flashes frequency and degree of bother over time.  Pearson correlation 
coefficients constructed against the other validated measures of menopausal symptoms 
were very high (all above 0.80).  Internal consistency, measured by Cronbach’s alpha, 
was also very high for each of the four domains. 
 The final Menopause-Specific Quality of Life Questionnaire contained four 
domains and 29 items, each on a Likert scale (Appendix A1). 
 
Scoring of the MENQOL 
 The systematic scoring for each of the four MENQOL domains is identical.  The 
seven-point Likert scale used during the administration of the MENQOL is converted for 
scoring and data analysis.  For each of the 29 items, this seven-point Likert scale is 
converted to an eight point scale, ranging from 1 to 8.  A “one” is equivalent to a woman 
responding “no”, indicating she has not experienced this symptom in the past month.  A 
“two” indicates that the woman experienced the symptom, but it was not at all 
bothersome.  Scores “three” through “eight” indicate increasing levels of bother 
experienced from the symptom, and correspond to the “1” though “6” check boxes on the 
MENQOL.  Once each item has been manipulated into a 1 – 8 score, each domain is 
scored by averaging the manipulated values.  Hence, the average for each domain is 
constrained between 1 (not at all a problem; respondent selected “no” for each item in 
the domain) to 8 (respondent reported experiencing each symptom in the domain at the 
highest degree of bother) (Appendix A2).   
 
Usage of the MENQOL 
 Traditionally, the MENQOL has been used in clinic-based populations among 
postmenopausal women with an intact uterus and naïve to hormone therapy (4-11).  The 
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limitations of using the tool in these populations have been small sample sizes and lack 
of generalizability to a broader general population of post-menopausal women. 
 When used in clinical trials to compare the efficacy of a drug to either a 
comparator medication or placebo, the MENQOL has shown that estrogen and 
estrogen-like compounds are effective in reducing bothersome hot flashes (4, 5, 9, 12).  
The MENQOL has also been used in hospital-based cross-sectional studies using a 
small, convenience sample (13, 14).  The use of the MENQOL in non-population-based 
studies has provided researchers with a large volume of information about quality of life 
of menopausal women, yet studies in population-based samples would further our 
knowledge of this topic. 
 
Limitations of the MENQOL 
 The MENQOL has traditionally been limited by its lack of use in population-based 
studies.  Though there is evidence that this is changing, given the increased use in other 
countries such as China and Chile, this instrument has yet to be used in a population-
based sample of the United States (15, 16).  Literature has supported the hypothesis 
that women of European descent differ from those in Asian and Hispanic cultures; thus, 
the generalizability of studies conducted outside the United States has little bearing on 
the understanding of quality of life among women in the United States (17).  Additionally, 
authors of the MENQOL constructed the domains based on importance score and not by 
factor analysis.  This method has been critiqued by other authors and is considered 
inferior when compared to the development of other instruments measuring menopausal 
quality of life (1). 
 It is an additional limitation that the finalized items in the MENQOL have been 
pre-selected by the instrument developers and that researchers do not have access to 
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the fully enumerated set of potential items, many of which did not make it into the final 
instrument, and all of which could have been used in factor analysis. 
 
The Need and Significance for Further Evaluation of the MENQOL 
 The MENQOL is an informative tool that is designed to detect and discriminate 
between four domains representing different constructs of quality of life.  This instrument 
has been used in various situations, typically pertaining to use in clinical trials.  The Food 
and Drug Administration recently has exerted more control over surveys and 
questionnaires which could be treated as patient-reported outcomes (18).  The 
enactment of this guidance occurred after the development of the MENQOL.  The 
authors have determined that there are four constructs under which all 29 questions 
should fall; however, this was not determined by factor analysis, and is a limitation of the 
instrument’s development.  It was conceivable that more or fewer domains would be 
sufficient to explain the various constructs of quality of life among postmenopausal 
women. 
 The MENQOL has demonstrated the stability of some psychometric properties, 
but not all.  Items that were selected in the early 1990s may not necessarily be of utmost 
importance to postmenopausal women’s quality of life today.  For instance, vaginal 
health is arguably a very important part of a woman’s quality of life, yet it is captured only 
in one question relating to vaginal dryness during intercourse.  For postmenopausal 
women who do not regularly engage in intercourse, the validity of this item is lost.  
Hence, it may be of use to evaluate whether or not the addition of such questions could 





The Epidemiology of Vasomotor Symptoms and Depression 
The Epidemiology of Vasomotor Symptoms 
 Vasomotor symptoms including hot flashes, night sweats and sweating are 
among one of the most commonly reported symptoms among menopausal women.  Hot 
flashes are a sudden sensation of warmth generally felt in the upper extremities and 
chest and are a common and bothersome symptom among peri- and postmenopausal 
women.  Symptoms that may indicate a hot flash (or hot flush) include changes in the 
temperature of the finger, hand, calf and forearm, in addition to common symptoms 
found in the cheek, forehead and chest (19).  Additionally, it has been noted that 
elevated core body temperature serves as a trigger for an upcoming hot flash (20).  
Vasodilation occurs following a hot flash, which may elicit shivering (21).  Hot flashes 
have been found to follow a circadian rhythmic pattern, with most bothersome hot 
flashes occurring in the evening.     
 The etiology of hot flashes is not well known, other than the hypothesis that they 
occur due to reduced estrogen associated with the menopausal transition.  Typically, hot 
flashes are a symptom caused by the decrease in estrogen, are hypothesized to 
manifest in a sharp peak soon after the last time of ovulation for a woman, and tend to 
decrease after a period of one to three years (22).  Serotonin synthesis maintains the 
thermoregulatory system in the hypothalamus.  A decrease in estrogen alters this 
thermoregulatory ratio between hyperthermic and hypothermic serotonin receptors, 
creating an unstable environment that is vulnerable to increased core temperatures and 
hot flashes (9).  
 The prevalence of hot flashes among menopausal women varies from study to 
study; a longitudinal study in Australia showed hot flash prevalence at approximately 
27%; and a population-based study of US women yielded a prevalence of hot flashes of 
75% among post-menopausal women 41-53 years old (19, 23-25).  This prevalence may 
 12
be as high as 95% for women in menopause transition (ages 52-56 years) (26).  These 
symptoms may be more prevalent among African American women, but such results are 
not substantiated by literature (27, 28).  There are several risk factors/predictors of hot 
flashes: having a mother who experienced hot flashes, higher body mass index (BMI), 
tobacco use, tubal sterilization, age, residence at higher altitude, stress, and depression 
have all been shown to be associated with menopausal hot flashes (29-36). 
 Treatment of hot flashes has typically been with hormone therapy (37).  
However, after the Women’s Health Initiative released results contradicting the 
previously reported cardiovascular benefits of Hormone Therapy (HT), the use of HT 
declined (38).  Yet, there is evidence that shows that the timing of initiation of HT is 
important, and that women may still reap benefits from using hormones on a short term 
basis (39).  In addition, complementary and alternative medicines are also used for the 
relief of hot flashes.  Due to the thermoregulatory system being regulated by serotonin, 
several classes of antidepressants have been used to treat hot flashes, with moderate 
success (4, 6, 9, 12).  Nearly three quarters of women would like to be able to take a 
nonhormonal agent that could reduce their bothersome hot flashes by 50% or more (40).  
 There is little disagreement that hot flashes occur naturally with the menopausal 
transition, but objective characterization for purposes of research has proved difficult.  
Some studies have measured the dichotomous existence of hot flashes (yes vs. no), as 
self-reported over the past month by study participants (41).  Others have used a 
continuous outcome based on the number of hot flashes experienced in the past 2 
weeks, known as a hot flash frequency score (28).  Although the frequency score is 
more thorough than a dichotomous measure, both outcomes ignore hot flash severity.  
Another way of categorizing hot flashes would be to take into account the severity of 
each hot flash.  This categorization has been used as an outcome in many studies and 
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seems to be a more effective way of measuring the impact on a woman’s daily 
functioning (42). 
 Perhaps the most efficient and useful way of measuring hot flashes and the 
impact on quality of life is to measure the amount that a woman is bothered by hot 
flashes or night sweats.  The Menopause-Specific Quality of Life Questionnaire 
measures the existence of, and degree of bother from, hot flashes, night sweats and 
sweating, along with many other common symptoms. 
  
Epidemiology of Depression 
 Depression is marked by a loss of interest or pleasure in doing things, constant 
depressed mood, loss of appetite, sleeplessness, feelings of guilt or low self-esteem, 
poor concentration, and low energy (43).  It has been noted that depression has a 
significant effect on quality of life, and that worldwide, it is the fourth leading contributor 
to the global burden of disease (43).  Clinical diagnosis is typically made using the 
Structured Clinical Interview for DSM-IV validated scale to be administered by a clinician 
(44).  Other tools have been produced to be administered in an interview of survey 
setting, such as the Edinburgh Depression Scale, and the Center for Epidemiological 
Studies- Depression Scale (45-50).   
 The prevalence of depressive symptoms during the menopausal transition is 
somewhere between 40 and 60 percent (26, 51).  Women with a history of clinical 
depression or postpartum depression are at a higher risk for experiencing depressive 
symptoms during the transition into menopause (52-55).  In general, depression is 
associated with reduced quality of life (56).  Well-conducted studies have shown that 
depression, specifically in the years surrounding menopause, has a significant impact on 
physical and mental well-being (57- 58).  Other literature has claimed that the 
menopausal transition has no effect on a decline in cognitive functioning (59).  Several 
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medications have been successful in alleviating depression, such as bupropion, 
venlafaxine, sertraline, escitalopram and allopregnanalone (60-67).  Some of these 
medications are also used, though not indicated for, the treatment of vasomotor 
symptoms.  Also, regular exercise programs have been noted to help reduce depression 
among post-menopausal women (68). 
 Four theories have been posited that may explain the increased incidence of 
depression during the menopausal transition (69).  The first, known as the symptom 
hypothesis, posits that increased vasomotor symptoms lead to depression.  The second, 
biochemical hypothesis, argues that vasomotor symptoms are purely a mediator, and 
that the driving factor causing menopause-associated depression is merely the 
decreasing estrogen.  The third hypothesis, the psychoanalytic view, maintains that 
depression is increased because the menopausal transition poses a threat to one’s self-
concept and role in life.  The fourth, social circumstances perspective, states that an 
increase in depression during the menopause is purely coincidental and may not be 
attributed to anything specifically menopause-related. 
 While both hot flashes and depression are common symptoms during the 
menopausal transition, the actual mechanism by which the two may be related is 
unclear.  Several studies have hypothesized various pathways, leading to a 
circumstance that is much like a “chicken or egg” situation.  The longitudinal studies that 
could substantiate the temporal relationship are costly and inefficient and have not been 
done.  However, it has been theorized that the changing levels of estrogen surrounding 
the menopausal transition may lead to increased vasomotor symptoms (hot flashes), 
which in turn, may increase the risk for depressive symptoms (27).  Other studies have 
found no association between vasomotor symptoms and depression, but are limited by 
small sample sizes (35).  Additionally, one study hypothesized that having low self-
esteem made coping with bothersome hot flashes more difficult (70). 
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The Need and Significance for an Association Study 
 Literature has identified that hot flashes and depression are both common 
symptoms in menopause (20).  There was a need to examine the association between 
these two conditions, especially since anti-depressants are currently being used to treat 
both depressive symptoms and hot flashes (71), yet are not as effective as hormone 
therapy for treatment of hot flashes.  Hence, it was important to recognize that if there 
was an association, and if a treatment was effective for both symptoms it could lead to 
an increase in quality of life for a subset of women transitioning through menopause.   
 Literature that assesses the specific overlap and association between the two 
was sparse and contradictory.  A study using factor analysis on menopausal symptoms 
found that two distinct domains emerged:  Vasomotor and Psychosocial domains (27).  
This study showed that the Vasomotor domain was more strongly associated with 
perimenopausal women and the Psychosocial domain was more strongly associated 
with postmenopausal women.  In contrast, other studies which conducted factor analysis 
showed that some domains of health-related quality of life are affected by the 
menopausal transition, but the psychosocial symptom domain was not one of them (72-
73).   
 Menopausal symptoms, such as hot flashes and depression, that are both highly 
prevalent are necessarily (though not sufficiently) associated.  Studies have suggested 
that prior psychological issues, health related behaviors, socioeconomic status and a 
woman’s attitude toward menopause may be potential effect measure modifiers or 
confounders (10, 24, 73).  This study controlled for many potential confounders and 
consider potential effect modifiers, as had not been previously done, in an attempt to 
evaluate the association more rigorously.  This is especially important given that 
depression and hot flashes are two of the most common menopausal symptoms (41, 
74).   
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 It was hypothesized that vasomotor and psychological symptoms were linked via 
the conceptual mechanism shown in Figure 1.  All women in this study were 
postmenopausal, and were considered “at risk” for hot flashes and depression.  To our 
knowledge, the specific link between the vasomotor and psychological domains had 
never been examined using the MENQOL Questionnaire, despite the fact that it is a well 
known, validated instrument.  We hypothesized that, over time, there was a distinct and 
direct relationship between increased vasomotor symptoms and subsequent 
psychological symptoms.   
 
Summary 
 The Menopause-Specific Quality of Life instrument is a valuable tool that was 
used to evaluate the existence and severity (via bothersome score) of menopausal 
symptoms.  While this instrument was created with the experience of many experts in 
the field, some symptoms, such as vaginal health, were potentially not captured well with 
this tool and other symptoms in the instrument were either ambiguous or redundant.  
Evaluating the efficiency of items in this tool through factor analysis was one objective of 
this dissertation.  The results of this factor analysis, which had previously never been 
conducted on the MENQOL, adds great amount of knowledge to the field.   
 The MENQOL instrument also provided a useful way of evaluating the 
association between vasomotor symptoms and depression because various components 
of psychological health and vasomotor symptoms are included.  Longitudinal analysis 
using the Menopause Epidemiology (MEPI) Study allowed me to explore the temporal 
relationship between these symptoms.  Understanding in more detail the impact that 
menopausal symptoms have on quality of life, and the association between specific 
symptoms, now provides researchers and physicians with a better picture of the impact 
of menopausal symptoms on daily life and may help guide treatment. 
CHAPTER III  
METHODS 
 
A. OVERVIEW OF METHODS 
 
 We evaluated the appropriateness of the Menopause-Specific Quality of Life 
Questionnaire (MENQOL) in a population-based sample of women aged 40-65 years in 
the United States.  To do so, we explored this instrument using factor analytic methods.   
Factor analysis, the standard by which many patient-reported instruments are 
constructed, had never been conducted on the MENQOL.  This resulted in a gap in the 
literature that was easily filled by this study.  The factor structure relating to each 
MENQOL item was challenged and developmental theories behind this covariate 
structure was tested.  We explored both the factor and covariate structure of the original 
MENQOL instrument and appended items relating to vaginal health.  This research 
added extensive knowledge to existing literature with respect to items that were 
appended or removed from the original instrument. 
 We also evaluated the relationship between vasomotor symptoms and 
psychological symptoms over time.  This was done using data from both the initial and 
follow-up Menopause Epidemiology Study.  Data on women were collected at two time 
points, in 2005 and 2007.  Longitudinal linear models were constructed to relate 
changing vasomotor scores from the MENQOL to changing psychosocial domain 
scores.  Covariates that modified or confounded this relationship were explored. 
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B.  STUDY DESIGN 
 
The Menopause Epidemiology Study 
 The Menopause Epidemiology (MEPI) Study is a population-based, cross-
sectional study designed to evaluate the prevalence and characteristics of menopausal 
symptoms among women 40-65 years old.  Participants were recruited from the 
KnowledgePanelSM held by Knowledge Networks.  The KnowledgePanelSM is based on 
random digit dialing (RDD) and probability sampling.  Those recruited by the 
KnowledgePanelSM who currently do not have Internet access were provided access free 
of charge.  Hence, this was not a convenience sample of Internet users and has been 
shown to be representative of the United States population (Table 1). 
 The survey was self-administered and participants were allowed to pause and 
continue the survey at their convenience.  Data was collected electronically as the 
participant advanced through the Internet-based survey.  Data collection took place 
nationally between April 1, 2005 and April 20, 2005. 
     The MEPI study investigators invited 6,201 women to participate, who were 
randomly selected from the approximate 11,400 women aged 40 to 65 years old in the 
KnowledgePanelSM; 1,278 women did not reply to the emailed invitation, 293 did not 
consent to the study, and 228 were ineligible (did not have a period in the previous 12 
months due to: a pregnancy in the last year, intra-uterine device, chemotherapy, 
strenuous exercise, anorexia, or other medical condition).  This left 4,402 women in the 
MEPI Study population (Figure 2). 
 Menopausal status was identified as pre-menopausal (n=1,267, no irregular 
periods in the previous 12 months, peri-menopausal (n=432, irregular periods less than 
12 months), or post-menopausal (n=2,703, cessation of menses for 12 months or 
longer).  Data for this study was restricted to postmenopausal women only. 
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The Menopause Epidemiology Follow-up Study 
 Following the data collection from the Menopause Epidemiology Study, a follow-
up study was conducted two years later in the same manner with women who had been 
participants in the first study.  Retention was approximately 60% between the two 
phases.  For the longitudinal analyses to be explored among this population, all eligible 
postmenopausal women who completed both the initial and follow up questionnaires 
were analyzed (n=1,506).  Statistics comparing the two MEPI populations are shown in 
Table 1.  KnowledgePanelSM panel members were enrolled on the panel for 3 years 
total, after which they were released from the Panel.  Thus, some of the loss of follow-up 
between the two phases of the study is likely to have occurred at random due to 




C.1  Aim #1 Methods 
 
Factor Analytic Methods   
 Factor analysis is a method of examining the degree to which various items in a 
questionnaire cluster together, or factor.  A factor is a representation of a specific 
construct.  Factor analysis seeks to look at the degree of covariance among 
questionnaire items that may in turn be expressed via a smaller number of constructs 
(factors).  The covariance structure between the items can be used to determine how 
many factors can be extracted from a set of questionnaire items, as tightly correlated 
items may often represent the same construct. 
 Factor analysis may be exploratory or confirmatory in nature.  Exploratory Factor 
Analysis (EFA) seeks to eliminate items which do not factor well into any one given 
construct and is typically used during instrument development.  That is, once an EFA is 
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conducted, items which appear to not factor well and are not correlated with other items 
may be eliminated from future versions of the instrument (75). 
 Confirmatory Factor Analysis (CFA) is a theory-testing method used once an 
instrument has already been developed and tested in a population to determine whether 
the properties and factors in a pre-established theory hold in an external population.  It is 
assumed that each variable within an instrument has a known factor with which it should 
cluster.   
 
Eigenvalues and Factor Extraction 
 
 There are two commonly used methods to determine how many factors are 
needed in a factor analysis:  The Eigenvalue Rule, and scree plots.  Eigenvalues in 
factor analysis are values that represent the amount of variability explained by the factor.  
In the Eigenvalue Rule, the number of factors to extract from a model is sometimes 
based on the number of factors with eigenvalues greater than 1.0.  However, this 
method, while frequently used, can be too liberal and lead to too many factor being 
extracted (76).  Scree plots are a graphical representation of each factor and are another 
method of factor extraction (77).  The factor extraction theory which uses scree plots 
implies that the total number of factors to be extracted is based on the function of the 
chart in which an elbow appears (Figure 3).  This elbow shows a sharp distinction 
between the number of factors that should be kept, and the number of factors which do 
not add enough to the explanation of variance. 
Parallel Analysis 
 When the number of factors to extract is difficult to determine via standards such 
as the Eigenvalue Rule or Scree plots, Parallel Analysis is sometimes used.  Whereas 
the Eigenvalue Rule works best on very large samples as the size reaches infinity, 
parallel analysis overcomes this limitation and is easily used in smaller samples (77).  
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Parallel analysis takes the same sample size and constructs a number of correlation 
matrices among random variables and compares them to the variables in the dataset.  
Factors associated with the actual eigenvalues that exceed those associated with the 
randomly generated eigenvalues are kept.  For this analysis, parallel analysis was run 
using 100 iterations to determine the most appropriate number of factors to extract. 
   
Orthogonality and Factor Rotation 
 The rotation of factors in factor analytic methods serves to provide the researcher 
with more interpretable factors.  Rotation will often alter factor loadings and change the 
percentage of variance explained by each eigenvalue.  Several types of rotation exist, 
and can be chosen based on the orthogonality of the factors.  Orthogonality is 
determined by the degree of independence between factors.  Perhaps the most 
conservative approach to factor rotation would be to assume complete independence 
between factors and to choose a varimax rotation.  While other methods of factor 
rotation will create a factor correlation matrix, varimax will not, because of the 
assumption that each factor’s correlation with any other factor is precisely 0.  A varimax 
rotation will provide high loadings on the relevant construct and low loadings on other 
factors, resulting in fewer cross-loadings and factors which are more interpretable.   
 However, it is often difficult to assume complete independence of factors, which 
makes promax rotation an efficient alternative.  Promax rotation is an oblique rotation 
which measures interfactor correlations before outputting a factor structure.  Examining 
these interfactor correlation coefficients can help to determine whether or not an oblique 
rotation is needed.  For instance, correlation coefficients in the order of 0.15 tell us that 
we are not gaining much with an oblique rotation (and that the factors are not tightly 
correlated) and we can be safe with an orthogonal rotation.   
Item Reduction 
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 Factor loadings were determined by the standardized regression coefficients.  
Items were considered candidates for exclusion if the associated factor loading was less 
than 0.40 (78).  Items were also deleted if they loaded on more than one factor, 
indicating ambiguity. 
Aim #1a.  Evaluation of Menopause Specific Quality of Life (MENQOL) 
Questionnaire. 
 
 To evaluate the appropriateness of the MENQOL in a population-based sample, 
both exploratory and confirmatory factor analysis were used.  The authors who 
developed the MENQOL previously determined that four domains (Vasomotor, 
Psychosocial, Physical, and Sexual) were sufficient to explain the constructs bound by 
the 29 MENQOL items.  The a priori hypothesis was that the items would filter into the 




 Data analysis for this aim was conducted using the 2,703 postmenopausal 
women from the initial Menopause Epidemiology Study.  These women were randomly 
split into two equal groups based on a uniform distribution.  Doing this avoided overfitting 
a model to the data.  Factor analysis was performed on one group, tested on the other 
group, and finally reported for the group as a whole. 
 Factor analysis was conducted in a exploratory nature, and factors were 
extracted using scree plots, the Eigenvalue Rule, and Parallel Analysis.  This approach 
used an oblique rotation for factor extraction, as complete independence between 
domains could not be assumed.  Reliability coefficients were calculated for each domain; 
those domains with coefficients exceeding 0.70 were considered to have good reliability 
(79). 
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 It was expected that the sexual and vasomotor domains would cluster well, 
based on the small number of items within each domain.  Items that did not correspond 
to the domains under which they were created were explored in further detail and 
potentially dropped according to the aforementioned criteria.  The goal for this analysis 
was to examine how well each item in the MENQOL holds to its theorized domain in a 
population-based study of postmenopausal women. 
Aim #1b  Potential Revision of the Menopause-Specific Quality of Life (MENQOL) 
Questionnaire. 
 
 Vaginal symptoms are also very common among women transitioning through 
menopause (25).  These symptoms have implications which affect a woman’s quality of 
life.  Prevalence estimates for vaginal symptoms range from ten to fifty percent (24, 80-
87).  Common symptoms include vaginal itching, irritation, dryness, and dyspareunia, 
but many women may not be symptomatic (88).   
 Given the high prevalence of bothersome vaginal symptoms during the 
menopausal transition, there is great potential for these symptoms to affect a woman’s 
quality of life.  The Menopause Epidemiology Study explored this possibility by adding 
six items to the existing MENQOL questionnaire relating to vaginal health, shown in 
Table 3.  Each item was asked in the same manner as the original MENQOL instrument; 
respondents first were asked to indicate whether they had experienced the problem in 
the past month (yes/no); if so, respondents rated the degree of bother on a scale from 0 
to 6.  These values were then rescaled on a 1 to 8 scale, with 1 indicating ‘symptom not 
experienced’, 2 indicating ‘symptom experienced but was not bothersome’ and 3 through 
8 indicated the ‘symptom was experienced’ with increasing levels of bother (Appendix A-
2). 
 These items were explored using an exploratory factor analysis because these 
items have never been examined in conjunction with the MENQOL before.  They had the 
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propensity to factor in several different ways, some of which are shown in Table 4.  
Similarly to Aim #1a, this analysis was also conducted on a split sample. 
 The number of factors extracted from this analysis was assessed in several 
ways.  First, SAS default settings allowed for an initial look at the factoring structure 
without restraints.  Next, the number of factors extracted was restricted by using scree 
plots and traditional eigenvalue thresholds to examine if the vaginal symptoms factored 
into one (or several) of the existing domains.  Third, parallel analysis was used to 
determine the appropriate number of factors to extract.  Varimax rotation was used to 
reduce the propensity for items to cross-load on multiple factors.   
 The results from the first aim helped determine if items were kept or removed 
from the existing MENQOL.  The second part of this aim was to restructure the original 
MENQOL, incorporating vaginal symptoms into the questionnaire where appropriate, 
and deleting items which did not load well.  
 
C.2 Aim #2 METHODS 
Aim #2.  Evaluation of the Relationship between Vasomotor Symptoms and 
Psychosocial Symptoms over time. 
 
 A longitudinal analysis was conducted to explore the relationship between 
change in vasomotor symptoms and a change in psychosocial symptoms.  Using the 
MENQOL instrument the two domains of focus were the vasomotor symptom domain 
and the psychosocial domain, controlling for a variety of related covariates.  To do this, 
we employed a change-score method for outcome of psychosocial symptoms, while 
controlling for baseline psychosocial score as an independent variable.  This method 
allowed us to examine the association between a change in vasomotor symptoms (either 
an increase or a decrease) with change in psychosocial domain scores from the 
MENQOL. 
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 The overall function that this analysis followed was: 
∆Psychosocial Domain = 
        ∆ VMS1 Domain + Baseline Psychosocial score + Baseline VMS score + Covariates 
 This formula deviates slightly from what has been taught in traditional longitudinal 
epidemiology studies in that this analysis was not restricted to those without 
psychosocial symptoms in baseline.  Instead, baseline psychosocial score was 
controlled for, which will allow us to see if there is a relationship with respect to not only 
an increasing psychosocial score, but a decreasing one as well.  Restricting to a 
population without any psychosocial symptoms at baseline would have only allowed us 
to see how the change in VMS domain score was associated with an increase in 
psychosocial score.   
 The main analysis for this aim was conducted using a linear regression, as 
maintaining the continuous nature of the outcome provided the most statistical power.  
However, the relationship was also explored using a dichotomous outcome variable 
using a cutoff of a 1.5 unit change to verify the results of the linear model.   
 
Outcome Assessment 
 Psychosocial symptoms were defined using the MENQOL scoring algorithm.  
The psychosocial outcome was explored using scoring that was both continuous and 
dichotomous.  Continuous scoring for the psychosocial domain change score was 
constructed by subtracting the baseline psychosocial domain score from the follow up 
psychosocial domain score and ranged from -7 to 7.   
 For the dichotomous outcome scoring, a cutpoint was placed to divide women 
who had a positive change greater than or equal to positive 1.5 units on the change 
score for psychosocial symptoms.  This resulted in an approximate ten percent cutpoint 
                                                 
1VMS = Vasomotor Score 
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and made logistic regression an appropriate decision.  Because literature had not yet 
established a longitudinal study in which the MENQOL has been assessed over time, 
this cutpoint seemed the most appropriate way to dichotomize this outcome.   
Exposure Assessment 
 Vasomotor symptoms were evaluated using the MENQOL scoring system for 
both the initial and the follow up study.  This continuous outcome was constructed by 
subtracting the baseline vasomotor domain score from the follow up vasomotor domain 
score and had a range spanning -7 to positive 7.   
Effect Measure Modification 
 Covariates from the baseline survey were used to assess potential effect 
measure modification.  The relationship between change in vasomotor domain score 
and change in psychosocial domain score were assessed within each level of each 
covariate to explore potential modifiers via stratification.  To assess any potential 
interaction, a priori  p-values were set at 0.10 for interaction terms in linear regression 
with the covariate*exposure terms.    
 For the logistic modeling, effect measure modification was assessed between the 
covariates and the exposure using the Breslow-Day test of homogeneity.  An a priori p-
value was set at 0.20 to determine if the covariate is an effect measure modifier for 
inclusion into the initial model (89).  
Confounding 
 Covariates that were determined to be effect measure modifiers remained in the 
model with their associated interaction terms for the logistic regression model.  Other 
covariates which did not meet the criteria for effect measure modification were then 
assessed for confounding.  Confounding was determined in three ways- via the 
relationship between covariate and exposure, covariate and outcome, and via a directed 
acyclic graph (Figure 4) (90).  The directed acyclic graph showed that all covariates lie 
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on unblocked back-door paths; thus, all covariates contained within the figure were 
evaluated for potential confounding and included in the full model. 
 Table 5 depicts the potential confounders for this analysis and their respective 
distributions.  Potential confounders were broadly lumped into the following constructs: 
demographics (age, race, income, marital status, and BMI), behavioral (physical activity 
and tobacco use), healthcare-related (hormone therapy, depression medication use) and 
reproductive (parity, hysterectomy, years since menopause), in addition to baseline VMS 
score, and baseline psychosocial score (Appendix A3).  Age, Body Mass Index, and 
years since menopause were assessed in the baseline survey continuously.  These 
variables were evaluated for normality via historgrams and remained continuous for this 
analysis.  All other covariates were categorical in nature. 
 The following covariates from the baseline survey were eliminated for the 
following reasons:  history of depression, and healthcare seeking for depression (high 
correlation with baseline psychosocial score), breast cancer (small n), healthcare 
seeking for hot flashes (high correlations with baseline hormone therapy use), and 
female sexual dysfunction (no relation to the exposure). 
Modeling Strategies 
 The relationship between vasomotor change score and psychosocial change 
score was primarily evaluated using a linear regression model, controlling for potential 
effect modifiers and confounders.  To confirm the results of the linear regression model, 
a logistic regression model was also used.  The outcome of change in psychosocial 
domain score for this logistic model was coded using a cutoff value of +1.500 units or 
greater, versus 1.499 or less.  In each model, a backward elimination approach was 
used, with a user-selected elimination based on highest p-value.   
 To examine the potential for confounding, covariates which alter the crude 
estimate between change in vasomotor domain score and change in psychosocial 
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domain score by more than ten percent will be considered confounders, and remain in 
the model (91).  Traditionally, this process is iterated until only important covariates 
remain in the model.  However, recent papers argue that if nonsignificant covariates do 
not alter the precision of the main effect, it is suitable to retain them in the model (92). 
 
Assessment of Missingness and Loss to Follow-up 
 For this analysis, formal assessment of missingness was not necessary.  The 
computer-automated nature of the MEPI provides hard prompts to the respondents 
when an item is requested to be skipped.  These hard prompts, while a second attempt 
to skip was successful, generally resulted in the respondent choosing an appropriate 
response.  There were few covariates with any missing data, and those with missing 
data were less than five percent.  Hence, a strict analysis of missing data (multiple 
imputation) was not needed here.  Missing values remained missing and were not 
imputed. 
 To evaluate the potential impact loss to follow-up, an analysis of baseline 
demographics and characteristics was conducted to examine those women who were 
postmenopausal at baseline and did not complete the follow-up study.  There was a 
similar distribution of all characteristics found (Appendix A4).  Hence, there was no 
reason to believe that our sample behaved any differently than the women who could 
have been eligible for participation in the follow-up study. 
 
Outliers 
 Five respondents were excluded from this analysis based on the value of their 
BMI being an extreme outlier.  Having a BMI less than 15 with extreme height and/or 
weight values, such as women reporting height greater than 7 feet with an associated 
weight of 130 pounds were determined to be improbable and were excluded.  Likewise, 
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women reporting a very short stature such as height less than 4 feet tall and an 
associated weight of over 250 were also excluded.   There were no other outliers found in 




 There were several sensitivity analyses that were conducted in this study to 
explore the relationship of vasomotor symptoms on psychosocial symptoms.  Despite 
the fact that hormone therapy and depression medication were not found to be effect 
modifiers, we also ran this model among those on and off hormone therapy and those 
one and off depression medication.  Additionally, I ran a fifth model on those not taking 
hormone therapy or depression medications.  All of these populations had similar 
demographic distributions as the study population (Appendix A5). 
 The outcome of psychosocial symptoms encompasses more than just 
depression.  To get a better understanding of how a change in vasomotor domain score 
effects the single item “Feeling Down, Depressed, or Blue” from the MENQOL, I 
additionally examined a model just on that one item (Appendix A6). 
 




 Statistical power for this aim was estimated using PS Power and Sample Size 
Calculator, version 2.1.3, 1997 (93).  The power for main effects in the MEPI population 
was estimated using an alpha level at 0.05, with a fixed sample size of 1,506.  Assuming 
0.23 probability of increase in hot flash among those with no change or decrease in 
psychosocial domain score with 313 participants with increasing vasomotor score, and a 
ratio of increasing psychosocial domain score  vs no change or decrease at 8.91, there 
is greater than 90 percent power to detect an odds ratio of 1.30.  We may maintain 
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greater than 80 percent power detecting an odds ratio as small as 1.20.  Table 6 shows 
alternate power calculations with a fixed sample size, using various expected effect 
sizes. 
Continuous Outcome 
 By measuring the change in psychosocial score domain continuously, we can 
calculate statistical power by estimating the difference in the change in mean domain 
scores, using a categorically scored change in vasomotor domain score.  Using an alpha 
level of 0.05, and a fixed ratio of those in increased vasomotor scores as compared to 
no change or decrease in vasomotor scores of 0.65 (with 899 with increased vasomotor 
score), and a standard deviation of 1.3 for the distribution of the continuous change in 
psychosocial domain score, we have over 99% power to detect a 0.5 unit change in 
psychosocial domain score.  Table 7 shows alternate power calculations for various unit 
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Objective: Despite being used in multiple studies, the Menopause-Specific Quality of 
Life Questionnaire (MENQOL) has not been assessed with factor analysis, a common 
method of item reduction in quality of life tools.  We also assessed the benefit of adding 
six candidate vaginal health items to the existing instrument. 
Design: The Menopause Epidemiology Study is a cross-sectional population-based 
study of women 40-65 years old in the United States chosen from a source population 
selected by random digit dialing and probability sampling.  We focused on 2,703 
postmenopausal women for our analyses.  Prior to analysis, and to prevent model 
overfitting, we split our sample into two equal groups using a uniform random sample.  
Using parallel analysis for factor extraction, we performed confirmatory and exploratory 
factor analysis on the MENQOL to examine the current factor structure and to evaluate 
the candidacy of six new items appended to the current MENQOL.  Reliability 
coefficients were calculated for each of the new domains. 
Results: With few exceptions, the items from the original MENQOL factored into the 
domains under which they were originally placed.  Five items were suggested for 
removal based on crossloading across domains (Difficulty Sleeping, Poor Memory, 
Accomplishing Less than I Used to, Changes in Appearance Texture or Tone of my Skin, 
and Feeling Tired).  Reliability coefficients for the four original domains were acceptable:  
Vasomotor, 0.86; Psychosocial, 0.84; Physical, 0.86; and Sexual, 0.78.  When six 
vaginal health items were added to the MENQOL, one was a candidate for exclusion 
based on poor factor loading (Vaginal Bleeding on Sex).  The other five items went into 
two domains, one into sexual (Vaginal Pain on Sex) and the other four into a new 
domain.  Reliability statistics for this five factor model were also acceptable: Vasomotor, 
0.86; Psychosocial, 0.84; Physical, 0.86; Sexual, 0.77; and Vaginal Health 0.67. 
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Conclusions:  Results from factor analysis indicate that the MENQOL would be 





 Menopause-related symptoms such as hot flashes, night sweats, weight gain, 
and decreased sexual functioning all have negative impacts on quality of life, and affect 
daily activities such as sleep, work, and leisure activities (94).  Health-related quality of 
life among menopausal women has long been a controversial topic in published 
literature.  Several instruments have been developed in an attempt to quantify these 
symptoms (1).   
 The Menopause-Specific Quality of Life (MENQOL) instrument was developed in 
1996 and has been used in various clinic and ethnic populations (4-11).  A 29-item 
questionnaire, the MENQOL aims to capture health-related QOL in areas centered 
around vasomotor, physical, psychosocial and sexual functioning (2).  One of the 
strengths of the MENQOL is its ability to not only gauge the frequency of these 
menopausal symptoms, but also to capture the degree of disruption in the woman’s life 
in the previous 30 days due to the menopausal symptoms.  Additionally, the MENQOL 
scoring is standardized among domains, because of the discordant number of items 
within each domain, creating the ability to draw comparisons between the different 
factors and their impact on a woman’s quality of life. 
 However, one of the limitations of the MENQOL that has been cited in literature 
is the lack of factor analytic methods performed on the instrument, a common method of 
item reduction of quality of life tools (95).  Additionally, the MENQOL in its current form 
does not capture many symptoms related to vaginal health, despite recent literature 
indicating that such symptoms may be strongly related to health-related quality of life 
(95).  Vaginal symptoms such as vaginal itching, irritation, dryness, and dyspareunia are 
very common among women transitioning through menopause, with prevalence 
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estimates ranging from ten to fifty percent (24, 25, 80-88).  These symptoms may also 
negatively impact quality of life (94).   
 While widely used and accepted as a quality of life instrument among 
postmenopausal women, this is the first study that performed a factor analysis on the 
MENQOL instrument using a population-based study of postmenopausal women in the 
United States.  Furthermore, this study assesses the value of augmenting the existing 
instrument with vaginal health items using exploratory factor analysis.   Proposed vaginal 
health Items assess dryness, irritation, itching, difficulty urinating, and pain during sexual 
activity.  These items are not currently captured in the existing MENQOL instrument and 
were therefore evaluated for potential inclusion.  The overall objective of this study was 




 This study population included the postmenopausal women from the Menopause 
Epidemiology (MEPI) Study, which is a population-based, cross-sectional study of  
women in the United States aged 40-65 conducted in April 2005 (94, 96).  The source 
population for our study was the Knowledge Networks (KN) panel, which was selected 
by random digit dialing and probability sampling.  Individuals who did not have access to 
the Internet were provided with free Web-TV and Internet service upon enrollment into 
the panel.  Because of this enrollment process, the KN panel is a reasonably 
representative sample of the US population and is not a convenience sample of Internet 
users (97). 
 When participant selection for the study began, there were approximately 11,000 
women aged 40-65 years on the Knowledge Networks panel.  Just over six thousand 
(n=6,201) women were randomly selected from this group and invited to participate in 
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the MEPI study.  There were 4,923 (79%) women who replied and 4,630 (75%) who 
consented to the study.  Exclusion criteria included missing periods in the last 12 months 
due to pregnancy, breastfeeding, intra-uterine device, chemotherapy, strenuous 
exercise, anorexia, or other medical condition that resulted in lack of a menstrual period 
other than menopause.  After exclusion criteria were applied, 4,402 women remained in 
the full MEPI study.  Postmenopausal status was defined by self-report of not having a 
period in the past 12 months (n=2,703) and included both naturally and surgically 
menopausal women.  Our analyses focus on these 2,703 postmenopausal women.  As 
part of our study, these women were administered the most current 29-item MENQOL at 
the time of the study period in 2005 (2).  
 Factor analysis is used to examine the degree of covariance among 
questionnaire items that may in turn be expressed via a smaller number of constructs 
(factors).  The covariance structure between the items can be used to determine how 
many factors can be extracted from a set of questionnaire items in light of the fact that 
tightly correlated items may often represent the same construct.  Factor analysis may be 
confirmatory or exploratory in nature.  Confirmatory Factor Analysis (CFA) is a theory-
testing method used once an instrument has already been developed and tested in a 
population to determine whether the properties and factors in a pre-established theory 
hold in an external population.  Exploratory Factor Analysis (EFA) seeks to eliminate 
items which do not factor well into any one given construct and is typically used during 
instrument development.  That is, once an EFA is conducted, items which appear to not 
factor well and are not correlated with other items may be eliminated from future 
versions of the instrument (75). 
 This study was conducted in two phases; first using confirmatory factor analytic 
techniques on the existing instrument and the second using exploratory factor analysis 
to evaluate the candidacy of six additional vaginal health items.  
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Phase I – Confirmatory Factor Analysis 
 Prior to performing the analysis, we randomly split the sample into two equal 
groups to prevent model overfitting.  By splitting the sample randomly and performing 
the factor analysis on each half and comparing results, we were able to confirm that the 
extraction and item reduction was valid.  To determine the number of factors to extract, 
two methods were used: scree plots and parallel analysis.  Scree plots were constructed 
and evaluated for a clear break in the amount of variability explained by the factor.  
Additionally, we used the Eigenvalue Rule as a guide to retain the number of factors with 
associated eigenvalues greater than 1.0.  However, this method, while used frequently, 
is not conservative and can lead to the suggestion of too many factors (76).  In such 
cases, parallel analysis may provide a more accurate representation of the appropriate 
number of factors to extract (77). 
 Factor analysis was conducted among each half of the sample using an oblique 
factor rotation and promax solution allowing non-independence in the correlation 
between the factors.  Items with loading less than 0.40 were considered weak and were 
removed from subsequent factor analyses.  Items that cross-loaded across more than 
one factor were considered candidates for exclusion from further factor analyses.  The 
two samples were compared for agreement and then the factor analysis was conducted 
on the full sample.  Once the final factor structure was determined, reliability coefficients 
were calculated for each factor for all women in the study population. 
Phase II – Exploratory Factor Analysis 
 To begin this phase of the study, we began with the restricted version of the 
MENQOL as found in Phase I.  To evaluate the candidacy of six vaginal health items, we 
asked the study population about recent (within the last 30 days) vaginal itching, 
irritation, pain, difficulty or burning during urination, vaginal pain associated with sexual 
activity, vaginal bleeding associated with sexual activity, or vaginal discharge.  These 
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items were asked in the same manner as MENQOL items and scored identically.  We 
then treated these items as if they were a part of the instrument and evaluated how they 
factored among the other items. 
 We conducted an exploratory factor analysis in the same manner as the first 
phase of this study.  Items loading less than 0.40 and those that cross-loaded were 
considered candidates for exclusion from the overall instrument.  Reliability coefficients 
were also constructed for the finalized version of the MENQOL with the added vaginal 
health items. 
RESULTS 
 Table 8 shows basic demographics of the overall Menopause Epidemiology 
Study and the subset of postmenopausal women from the MEPI study as compared to 
the Current Population Study (97).  The Menopause Epidemiology study is a fairly 
representative sample of women aged 40-65 in the United States (96).  Compared to the 
US population, there is a slightly smaller percent of women 40-44 years old which is 
likely due to the MEPI exclusion criteria of pregnancy, breastfeeding, and IUD use.  
There were fewer women in MEPI with less than a high school diploma, which is 
indicative of a slightly more educated population than the United States. 
 In the analyses presented here, 84.0% (n=2,270) were aged 50 years or older, 
slightly more than three quarters (80%, n=2,171) were of White/Non-Hispanic 
race/ethnicity, and 23% (n=619) held a Bachelor’s or higher degree (Table 8). 
Phase I 
 Parallel analysis suggested the extraction of four domains from the existing 
MENQOL instrument (77).  With few exceptions, the items in the MENQOL 
overwhelmingly factored into the domains under which they were placed originally.  The 
vasomotor domain contained its original items (hot flashes or flushes, night sweats and 
sweating) and the sexual domain contained its original items (avoiding intimacy, 
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decreased sexual desire and vaginal dryness).  The psychosocial domain contained all 
of its original items with the exception of one: ‘Accomplishing Less than I Used To’ did 
not load into the Psychosocial domain.  It instead loaded into the physical domain.  All 
other items from the physical domain remained the same. 
 With a four factor extraction from the study sample, one item was a candidate for 
exclusion based on item loading less than 0.40 (Difficulty Sleeping, item loading: 0.29) 
(Table 9).  Several other items were poor items based on crossloading across factors: 
‘Feeling Tired or Worn Out’, ‘Accomplishing Less Than I Used To’, ‘Changes in 
Appearance, Texture or Tone of your Skin’, ‘Difficulty Sleeping’, and ‘Poor Memory’.  
These 5 items were removed from the questionnaire, and the data were re-analyzed.  
After the removal of these 5 items, the remaining items factored well with similar factor 
loadings; not further item reduction was required.   
 The revised factor analysis showed that the remaining items clustered well under 
the domains in which they were originally placed.  These clusters were then tested on 
the other random half of the sample, and additionally on the full sample.  Table 3 shows 
the results as tested on the full sample of postmenopausal women.   
Reliability 
 Reliability coefficients were constructed for each domain of the revised 
MENQOL.  Cronbach’s Alpha statistics were acceptable for each of the domains (Table 
10).  The sexual domain alpha was 0.78, the physical domain alpha was 0.86, the 
vasomotor domain alpha was also 0.86, and the psychosocial domain alpha was 0.84. 
Interfactor Correlations 
 The correlations between factors are shown in Table 11.  These results indicate 
moderate degree of correlation (0.3-0.5) between the factors and confirms that the 




 An exploratory factor analysis was run in Phase II to evaluate the candidacy of 
six vaginal health items to the revised MENQOL questionnaire found in Phase I.  
Similarly to Phase I, these analyses were run on each half of a uniformly randomized 
split sample, and again on the sample as a whole.  The six vaginal health items included 
‘Vaginal Irritation’, ‘Vaginal Itching’, ‘Vaginal Discharge’, ‘Vaginal Bleeding on Sex’, 
‘Vaginal Pain on Sex’, and ‘Vaginal Pain, Difficulty or Burning During Urination’.   
 Since it was unclear how many factors we should extract with the additional 
items, we again used parallel analysis to guide extraction techniques.  Based on the 
parallel analysis results, five factors were extracted.   
 Table 12 shows the factor loadings for the revised MENQOL from phase I with 
the addition of the six vaginal health items.  The supplemental items did not all factor into 
one additional domain; two of the items factored into the sexual domain and the other 
four clustered into a new domain.  ‘Vaginal Pain on Sex’ and ‘Vaginal Bleeding on Sex’ 
clustered on the Sexual Domain, although the loading on ‘Vaginal Bleeding on Sex’ was 
under 0.40 and was therefore a candidate for elimination (Table 12).  The other four 
items, ‘Vaginal Irritation’, ‘Vaginal Itching’, ‘Vaginal Discharge, and ‘Vaginal Pain, 
Difficulty and Burning During Urination’ constituted a new Vaginal Health domain. 
 ‘Vaginal Bleeding on Sex’ was eliminated from the revised MENQOL and the 
data were re-analyzed.  Without this item, the rest of the items held firmly to the same 
domains with good factor loadings (Table 13).  
 The data in Table 13 show what we consider to be the final, revised MENQOL, 
eliminating the original ambiguous items and adding in the pertinent vaginal health 
items.  The subsequent five appended vaginal health items clustered into two domains, 
‘vaginal pain on sex’ with the sexual domain, and the others into a new domain (Vaginal 
Health).   
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Reliability  
 Reliability for each of the five domains for the revised MENQOL was also 
acceptable.  The vasomotor and physical domains each had reliability coefficients of 
0.86, the psychosocial domain had a reliability coefficient of 0.84, and the sexual domain 
with the added item had reliability of 0.77.  The new domain, comprising the remaining 
appended vaginal health items, retained a coefficient of 0.67, slightly lower than the 
standard 0.70 recommended for adequate reliability (79). 
Interfactor Correlations 
 Interfactor correlations are shown for the five-factor MENQOL in Table 14.  
Correlations between factors were slightly lower than shown in Table 4, but still show 
that the oblique rotation used in the factor analysis was appropriate.  Coefficients ranged 
from 0.18 (vaginal health and psychosocial domains) to 0.55 (psychosocial and physical 
domains). 
DISCUSSION 
 The Menopause-Specific Quality of Life Questionnaire is a useful tool than can 
be used to evaluate frequent and bothersome symptoms in a postmenopausal 
population.  The existing tool explored symptoms as they impacted a woman’s life over 
four domains; vasomotor, psychosocial, physical and sexual.  This is the first study to 
evaluate the existing tool using a factor analytic approach to eliminate items that were 
ambiguous across more than one domain or that had poor factor loading indicating 
weakness as an item.  This has been a criticism of this tool in the literature and we 
aimed to address this issue in this paper.  Items which loaded on more than one domain 
included ‘Feeling Tired or Worn Out’, ‘Accomplishing Less Than I Used To’, ‘Changes in 
Appearance, Texture or Tone of Your Skin’, ‘Difficulty Sleeping’, and ‘Poor Memory’ and 
were removed based on ambiguity. 
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 The second phase of this study appended the abbreviated MENQOL by adding 
pertinent vaginal health items which may also impact a woman’s quality of life.  The 
vaginal health items that we included are strongly related to vaginal atrophy and were 
found to cluster both on their own and with the sexual domain, which can be reasonably 
expected given their nature. 
 This study is not without its limitations.  First, we began our factor analysis with 
only the 29 items in the original MENQOL.  Traditionally, item reduction and exploratory 
factor analysis is conducted on the entire set of potential items, to which we did not have 
access.  However, the results here hold largely to the expected domains.  Second, the 
reliability of the vaginal health domain for the added vaginal health items is 0.67, slightly 
below the accepted reliability level of 0.70.  The addition of one or two related items to 
this domain may improve this reliability coefficient.  These items could be generated 
through focus groups or suggestions from key opinion leaders in the field.  Yet, the 
coefficient is close to 0.70 giving us confidence that these important items should remain 
in the suggested version of this instrument. 
 This study has several strengths.  The Menopause Epidemiology Study 
population from which the data for this analysis were derived is a large population-based 
study and is generally representative of women 40-65 years old in the United States.  
The privacy of the data collection method over the Internet encourages truthful 
responses, which are particularly useful in a factor analysis approach in determining 
which items cluster with each other within domains.  Furthermore, to ensure that we 
were not overfitting our data to our factor analysis models, the models presented here 
have been confirmed after being run on both a split sample.  Also, the elimination of 
unnecessary items reduces the time it takes women to respond to the questionnaire, yet 
provides similar data to yield high quality results to the researcher or physician collecting 
the data.  Lastly, the addition of the vaginal health items asked in the same manner 
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ensured the ability to combine them with the MENQOL domains since the items were 
scored in the same manner.  
 We present here a final revised MENQOL, a 29 item questionnaire, which 
eliminated five of the original items and appended five vaginal health items.  Scoring for 




Paper 2: Longitudinal Association Between Vasomotor Symptoms and 
Psychosocial Outcomes among Postmenopausal Women in the United States: a 
Population-Based Study 
 
Running title: Vasomotor Symptoms and Psychosocial Outcomes 
 
Kristen B Van Dole, MSPH1, Rachel E Williams, PhD MS, Rebekkah S Dann, DrPH, 
Bradley Gaynes, MD, MPH, Robert DeVellis PhD, Michele Jonsson Funk PhD 
 
1Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, 
NC 
 
This research was funded by GlaxoSmithKline. 
 
Corresponding Author and Reprint Requests: 
 
Kristen B Van Dole, MSPH 
Department of Epidemiology 
CB #7435 
University of North Carolina at Chapel Hill 





Disclosure summary: K.B.V. received an unrestricted educational grant from 
GlaxoSmithKline and is a recipient of a Merck Foundation Pre-Doctoral Fellowship in 
Pharmacoepidemiology.  R.E.W. is an employee of GlaxoSmithKline and has equity 
interest in GlaxoSmithKline.   
 




Objective: While both vasomotor and psychosocial symptoms persist as common 
manifestations of the menopausal transition, their explicit association is unclear.  We 
investigated this association among post-menopausal women over a two year period. 
Design: The Menopause Epidemiology Study is a cross-sectional population-based 
study of women 40-65 years old in the United States chosen from a source population 
selected by random digit dialing and probability sampling.  We then followed up 
participants two years later, including only women who were postmenopausal at 
baseline and at follow-up (n=1,506) in the analyses.  The MENQOL vasomotor domain 
was used to assess vasomotor symptoms and the MENQOL psychosocial domain was 
used to assess psychosocial symptoms in this population.  The change in symptoms 
was defined as the difference in the MENQOL domain score from baseline to follow-up 
two years later.  Demographic information, behavioral activities, reproductive history and 
medication use were included as covariates in the models and were evaluated for effect 
modification and confounding.  Covariate-adjusted linear regression was used to assess 
the independent relationship between the change in vasomotor symptoms and the 
change in psychosocial symptoms.   
Results:  Approximately 25% (n=375) of the women reported an increase in vasomotor 
symptoms, specifically the degree of bother, over the two-year study period.  A larger 
proportion of women experienced an increase in psychosocial symptoms over the two-
year period (41%, n=619).  Twenty-two percent of the women reported an increase in 
both vasomotor and psychosocial symptoms over time.  A one unit increase in the 
vasomotor domain was associated with a 0.21 (95% CI: 0.12, 0.29) unit increase in the 
psychosocial domain among smokers, after adjustment for demographic, behavioral, 
medication use, and reproductive history covariates.  This association was stronger 
(0.29, 95% CI: 0.20, 0.39) among past or never smokers.  
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Conclusions:  This study provides further evidence of an association between 
vasomotor symptoms and psychosocial symptoms using a validated instrument in a 
population-based study.  There is a small but significant increase in psychosocial 
symptoms with increasing vasomotor symptoms.  Clinicians may want to take note of 
this association when treating postmenopausal women with either condition. 




  Hot flashes are hypothesized to be a symptom caused by the decrease in 
estrogen associated with the menopausal transition.  Hot flashes manifest themselves 
via a sharp peak soon after the last time of ovulation for a woman and tend to decrease 
after a period of one to three years (22).  The prevalence of hot flashes among post-
menopausal women in the United States varies from study to study; two recent 
population-based studies have shown the prevalence of hot flashes to range from 59% 
to 75% (25, 98).  Hot flashes are also prevalent worldwide; a longitudinal study in 
Australia showed hot flash prevalence at approximately 27% (24) and a study conducted 
in Australia among Indian women found the prevalence of hot flashes to be 34% (23). 
 The characterization and impact on quality of life of these vasomotor symptoms 
is assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire.  
The MENQOL is a 29-item validated tool that measures the existence of, and degree of 
bother from, hot flashes, night sweats and sweating, along with many other common 
menopausal symptoms such as psychosocial, physical and sexual symptoms (2). 
 It has been noted that depression has a significant effect on quality of life; 
worldwide it is the fourth leading contributor to the global burden of disease (43).  This 
condition is marked by a loss of interest or pleasure in doing things, constant depressed 
mood, loss of appetite, sleeplessness, feelings of guilt or low self-esteem, poor 
concentration, and low energy.  The prevalence of depressive symptoms during the 
menopausal transition is somewhere between 40 and 60 percent (26, 51).  In general, 
depression is associated with reduced quality of life (56).  Well-conducted studies have 
shown that depression, specifically in the years surrounding menopause, has a 
significant impact on physical and mental well-being (57-58).   
 The association between hot flashes and depression is not well understood, 
although both are highly prevalent during menopause.  Studies have suggested that 
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prior psychological issues, health related behaviors, socioeconomic status and a 
woman’s attitude toward menopause may confound the relationship between vasomotor 
and psychosocial symptoms (10, 24, 73).  The objective of this analysis is to evaluate 
the relationship between vasomotor symptoms and depression more rigorously by 
controlling for many potential confounders and evaluating potential effect modifiers, as 
has not been previously done to our knowledge.  
 
METHODS 
 Study Population 
 
 The study population included postmenopausal women who participated in the 
original and follow-up Menopause Epidemiology (MEPI) Study.  The original MEPI study 
was a cross-sectional, population-based study of 4,402 women 40-65 years old in the 
United States, collected in April 2005 (94, 96, 99).  The source population for this study 
was based on the Knowledge Networks (KN) KnowledgePanelSM
.
  This panel was 
selected via random digit dialing and members who did not have internet access at 
home were provided access free of charge. Thus, the KN panel is a reasonably 
representative sample of the US population, rather than a convenience sample of 
Internet users. 
 When participant selection for the study began, there were approximately 11,000 
women aged 40-65 years on the Knowledge Networks panel.  Just over six thousand 
(n=6,201) women were randomly selected from this group and invited to participate in 
the MEPI study.  There were 4,923 (79%) women who replied and 4,630 (75%) who 
consented to the study.  Exclusion criteria included missing menstrual periods in the last 
12 months due to pregnancy, breastfeeding, intra-uterine device, chemotherapy, 
strenuous exercise, anorexia, or other medical condition that resulted in lack of a 
menstrual period.  After exclusion criteria were applied, 4,402 women remained in the 
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study.  Postmenopausal status (both natural and surgical) was self-reported and was 
defined by not having a period in the past 12 months (n=2,703).    
 A follow-up study was conducted two years later in April 2007 among women 
who had been participants in the first study.  Women were asked the same questions 
that were in the original study, allowing for direct comparison of their responses over the 
two-year period.  Retention was approximately 60% between the two phases.  All eligible 
postmenopausal women who completed both the initial and follow up questionnaires 
(n=1,506) were used in this longitudinal analysis.  Summaries of the original and follow-
up MEPI populations are shown in Table 1.  By study design, KnowledgePanelSM 
members are enrolled for three years total, after which they are released from the Panel.  
Thus, some loss to follow-up between the two phases of the MEPI study likely occurred 
at random due to participants’ completion of three years of overall panel participation.   
Measures 
 The outcome of interest, change in psychosocial symptoms, was assessed using 
the psychosocial domain of the MENQOL.  The change over time was calculated as the 
follow-up psychosocial domain score minus the original psychosocial domain score, 
which yields values between (-) 7 to (+) 7. 
 The MENQOL vasomotor domain was used as a measure of vasomotor 
symptoms.  The change in the vasomotor domain score over the two-year period was 
constructed by subtracting the original vasomotor score from the follow-up vasomotor 
score, creating a continuous score ranging from (-) 7 to (+) 7.   
 Baseline covariates were assessed in 2005 at the time of the original survey.   
Demographic and socioeconomic status variables were age, race, marital status, and 
income level.  Health behavior factors were smoking status, body mass index, and level 
of physical activity.  Reproductive history covariates were history of hysterectomy and/or 
oophorectomy, parity, and the number of years that had passed since the start of 
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menopause.  Use of hormone therapy (HT) and depression medication was also 
included as a covariate.  Age, body mass index, and the number of years since 
menopause were assessed for normality using historgrams and included as continuous 
variables.  All other covariates were categorical in nature. 
Statistical Analyses   
 The objective of the analyses was to evaluate the relationship between 
vasomotor symptoms and depressive symptoms over time.  Prior to modeling, effect 
modification was explored using stratification by the covariates individually to determine 
the need for any potential interaction terms.  Linear regression was used with a 
backwards elimination approach to evaluate the association between vasomotor 
symptoms and psychosocial symptoms.  Candidate confounders were selected based 
on biologic plausibility, association with both vasomotor symptoms and psychosocial 
symptoms, and the use of a directed acyclic graph (90).  Baseline scores for vasomotor 
symptoms and depression were also controlled for in the models.  Confounding 
variables were assessed via a ten percent change in estimate of the beta during 
modeling. 
 To explore this association further, we conducted the same analysis restricted to 
several different subpopulations:  postmenopausal women on hormone therapy (n=298), 
postmenopausal women not on hormone therapy (1,208), postmenopausal women on 
depression medication (n=415), postmenopausal women not on depression medication 
(n=1,019), and postmenopausal women not on any depression or hormone therapy 
(n=840). 
 As a sensitivity analysis, these analyses were also run using logistic regression 
on the full model, classifying the outcome as dichotomous with a change greater than or 
equal to 1.5 units and less than 1.5 units.  Potential confounders were evaluated in the 
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same manner, and effect measure modifiers were identified using Breslow-Day test of 
homogeneity with a p-value set at 0.20.   
RESULTS 
 In these analyses, 86% (n=1,297) of the women were aged 50 years or older at 
baseline, over three-quarters were White non-Hispanic (82.5%, n=1,242), and just over 
25 percent (n=383) had a Bachelors degree or higher (Table 15).  The baseline study 
population of the Menopause Epidemiology Study and its follow-up cohort are well 
representative of the United States, as compared to the US Current Population Survey 
(96) (Table 15).  The exclusion criteria for the MEPI study, including pregnancy, use of 
any contraceptive device, or use of birth control, could be a reason for this age 
discrepancy between the CPS and the overall MEPI population.  The postmenopausal 
women remaining in the follow-up survey maintained similar demographics as those in 
the baseline and the US Current Population Survey, with the exception of being slightly 
older as expected since they were postmenopausal.    
 Change in vasomotor score was assessed continuously.  The distribution of 
these scores was approximately normal; median and mode change score was zero.  
Mean change score was (-) 0.35.  Approximately 25% (n=375) of the women reported an 
increase in the degree of bother from their hot flashes.  Likewise, change in 
psychosocial score was assessed continuously.  The distribution of these scores was 
also approximately normal as assessed via histograms; median change score was zero.   
The mean change score for psychosocial symptoms was (-) 0.13.  Over forty percent 
(41%, n=618) of the women reported an increase in their psychosocial symptoms over 
time.  Nearly twenty-three percent (n=334) of the women noted an increase in both 
vasomotor and psychosocial scores over the two-year study period; only 1.75% (n=25) 
reported a decrease in both symptoms.   
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 The unadjusted model showed that for every one-unit increase in the vasomotor 
domain score, the average increase in the psychosocial score was 0.20 (95% CI 0.16, 
0.24, p<0.0001). 
 Smoking status, categorized as smoking “currently or some days” versus “past or 
never” was found to modify the association between the vasomotor domain score and 
the psychosocial domain score, as assessed via stratification.  In the fully adjusted 
model, for every one-unit change in  the vasomotor domain, the average change in 
psychosocial domain score after two years for current smokers was 0.21 (95% CI: 0.12, 
0.29; p<0.0001), after controlling for all covariates (Table 16).  For past or never 
smokers, the association was stronger; for every one point increase in the vasomotor 
score over the two-year study period, the psychosocial domain score was increased by 
0.29 (95% CI: 0.20, 0.39; p<0.0001).  The only statistically significant predictors of 
change in psychosocial score were baseline vasomotor score, baseline psychosocial 
score, and smoking.  However, because there was very little precision gained by 
reducing the number of covariates in the model, we report results from the full model 
(92).    
 These results were confirmed with logistic regression.  No effect modifiers were 
found, and the final model contained the same confounders as the linear regression.  
However, because precision was not altered, all covariates were retained in the model.  
The final logistic regression model produced an odds ratio of 1.29 (95% CI 1.14, 1.44). 
 When subpopulations were examined among those taking (and not taking) 
hormone therapy, those taking (and not taking) depression medication, and those on no 
medication at all, all the models found similar results (Table 17).   
 Because tobacco use was found to modify the association between change in 
vasomotor score and change in psychosocial score, and because the psychosocial 
score measure includes an item which takes anxiety into account, a sensitivity analysis 
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was conducted to explore the effect on an item which measures depression only.  The 
change score of One item from the psychosocial domain, “Feeling Depressed, Down, or 
Blue” was used as the outcome and the model was reanalyzed.  The results of this 
model did not change;  the main effect estimate was similar to that of the full model 
(Appendix A6). 
DISCUSSION 
 This study found a positive association between an increase in vasomotor 
symptoms and increase in psychosocial symptoms.  These results confirm what has 
often been hypothesized in literature.  There was a difference found in the association 
between vasomotor symptoms and psychosocial symptoms between women who are 
current smokers and those who are former/never smokers.  The association between 
change in vasomotor score and change in psychosocial score is weaker for women who 
are current smokers, perhaps because tobacco use serves as a coping mechanism.  It is 
important to note that the definition of our outcome is broadly defined and included 
anxiety, which could be highly linked to tobacco use. 
 Using different measures to describe outcomes of psychosocial symptoms, other 
studies have found that vasomotor symptoms are statistically significantly associated 
with psychological symptoms (100).  One study used several different models to 
examine predictors of being blue for ≥ 6 days in the past two weeks, feeling irritable ≥ 6 
days in the past two weeks, feeling nervous ≥ 6 days in the past two weeks, and having 
a depressed mood for ≥ 6 days in the past two weeks (101).  Vasomotor symptoms were 
significantly associated in all models.  The results presented here are similar, except 
combine all of these outcomes into one cohesive domain, representing one latent 
variable of psychosocial symptoms.  Similarly, another study has found that the inability 
to cope with hot flashes leads to increasing depressive symptoms, which is consistent 
with the results seen in this study (70). 
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 Other studies have found that an association between hot flashes and 
depression persists among pre- and perimenopausal women but that the association 
was not statistically significant among postmenopausal women (41).  This association 
may have been lost due to the cross-sectional nature of the study. 
 Although this study provides further evidence of the association between change 
in vasomotor symptoms and psychosocial symptoms, this study is not without limitations.  
First, this study pertains only to those who entered our study as postmenopausal and 
remained postmenopausal throughout the study period.  Thus, in a perimenopausal 
period when vasomotor symptoms may be fluctuating more, this variability is not 
evaluated in our study.  This is due to the use of the MENQOL to define our exposure, 
which is validated only in postmenopausal women.  It may be conceivable that if 
perimenopausal women had been included, the positive association may have been 
stronger.  Second, our outcome of psychosocial symptoms is not equivalent to a 
clinically diagnosable condition of depression, but rather a self-reported construct of 
various symptoms representing mood fluctuations.  Third, we recognize the possibility 
for selection bias in this study.  In the period between the baseline and follow up study, if 
women who were exhibiting more psychosocial symptoms were less likely to participate 
in the follow up study, this may have weakened the observed association, and this is 
important to acknowledge.  Finally, it is of importance to note that there are additional 
external factors such as serotonin levels or changing estrogen which may have an 
important impact on the association, but which go unmeasured in this study. 
 The use of the MENQOL questionnaire also is a strength of this study.  Although 
there may be other measurements for vasomotor and psychosocial symptoms, the 
MENQOL is standardized and validated in this postmenopausal population (2).  It allows 
us to quantify change in the domains of interest while taking into account multiple 
aspects of these conditions.  The measures we used to evaluate both the exposure and 
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the outcome encompass a variety of symptoms that incorporate the degree of bother, 
instead of just one symptom coded dichotomously.  This is a novel approach to 
evaluating the association between the change in vasomotor and psychosocial 
symptoms that has not been shown in the literature.  Other strengths of this study 
include the representativeness of the population and the study design.  The Menopause 
Epidemiology Study is well representative of the United States population and the follow-
up study maintained a good response rate.   
 An additional strength of this study was our ability to perform a sensitivity 
analysis and stratify on various subpopulations, restricting among those taking and not 
taking both hormone therapy and medications indicated for depression.  Several 
medications have been successful in alleviating depression, such as bupropion, 
venlafaxine, sertraline, escitalopram and allopregnanalone (60-67).  Some of these 
medications are also used, though not indicated for, the treatment of vasomotor 
symptoms.  Because of this, it is important to note that medication use, either for the 
treatment of vasomotor symptoms or for depression, could be an important confounder.  
Our results provide evidence that regardless of medications being taken, that there is an 
association between vasomotor symptoms and psychosocial symptoms. 
 The longitudinal nature of this study allows us to draw conclusions about the 
association that vasomotor symptoms have on psychosocial symptoms in the 
postmenopausal period.  This is a large study which shows that over time, there is a 
positive association linking increased vasomotor symptoms to subsequent reporting of 
increased psychosocial symptoms, including feelings of isolation, anxiety, decreased 
accomplishment, and depression.  We evaluated a large number of potential predictors 
and found very few that were actual confounders of the association.   
 There are important clinical conclusions that can be drawn from this study.  The 
MENQOL is frequently used in clinic populations and can now help guide physicians in 
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the treatment of patients.  Clinicians seeing women over time with complaints of 
vasomotor symptoms should be sensitive to the potential for increased psychosocial 
symptoms.  These symptoms encompass more than just depression, and may be 
indicative of anxiety, feelings of isolation, and lack of productivity.   
 It is well documented that vasomotor and psychosocial symptoms are common 
during the postmenopausal period, but this is the first population-based longitudinal 
study completed in the United States that examines this explicit association.  Further 
research is warranted using clinically-based definitions of depression to confirm the 








 The Menopause-Specific Quality of Life Questionnaire is a validated tool used in 
post-menopausal women in many populations.  The existing tool is efficiently designed 
to measure four domains of a postmenopausal woman’s quality of life.  With areas such 
as vasomotor symptoms, psychosocial symptoms, physical and sexual symptoms, it 
seeks to tap all aspects of life not only in terms of frequency but also degree of bother.   
 One of the criticisms of the MENQOL was that it had never been evaluated for its 
psychometric properties via factor analysis.  This criticism has since been rectified with 
positive results from this dissertation.  The items factored well with a minor amount of 
crossloading between domains.  However, five items were candidates for exclusion: 
Difficulty Sleeping, Poor Memory, Accomplishing Less Than I Used To, Changes in 
Appearance, Texture, or Tone of My Skin, and Feeling Tired.  These items were likely 
excluded based on ambiguity due to physical and emotional interpretations.  Without 
these items in the existing MENQOL, the items then factored well into the domains 
under which they were suggested.   
 The first part of this study adds to the literature a wealth of information, not only 
by conducting a frequently-used method of psychometric testing on the instrument, but 
also by suggesting the deletion of unnecessary items from the tool which are not 
needed, and only add burden to the respondent filling it out. 
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 The second part of this study appended pertinent information to the MENQOL by 
adding items relating to vaginal health to the existing instrument.  These items were 
selected for inclusion to the instrument based on their significance in vulvovaginal 
atrophy as commonly reported symptoms.  Five of the six candidate items remained in 
the instrument after exploratory factor analysis was conducted.  The sixth, “Vaginal 
Bleeding on Sexual Activity” was suggested for exclusion based on poor loading and 
was indicative of a poorly worded or unimportant item. 
 After the exclusion of the five existing items and the one new vaginal health item 
that were not needed, and the addition of the five new vaginal health items, this newer 
version of the modified MENQOL provides an revised version of a quality of life tool 
which encompasses an entirely new domain of important items.   
 We suggest the modification of the existing MENQOL instrument, based on the 
factor analysis performed herein.  In clinic settings, this revised version provides new 
and important information to physicians and patients alike.  Patients will be able to 
accurately and discreetly report any vaginal symptoms they may be experiencing (as 
well as degree of bother) without fear of as much embarrassment as bringing it up 
verbally.  Additionally, physicians will be able to take the information from their patients 
and accurately assess and treat their patients therapeutically as needed. 
 Physicians may also be able to make better treatment decisions based on the 
results shown from the second aim presented here.  Until this study, the relationship 
between vasomotor symptoms and psychosocial symptoms has been speculated, but 
not well quantified among postmenopausal women.  Controlling for many potential effect 
modifiers and confounders, this study found a statistically significant relationship 
between changing vasomotor scores and changes in psychosocial scores.  Moreover, 
smoking status modified this association.  While the association was still significantly 
positive, women who smoked were less likely to experience an increase in psychosocial 
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symptoms as a result of increasing vasomotor score.  This is likely due to cigarettes 
being used as a mechanism for not being able to cope with the bothersome vasomotor 
symptoms.  Sensitivity analyses conducted among several populations showed the 
same results.  Smoking was found to modify the association in women who were not on 
hormone therapy, and in women not on any therapy at all.   
 Naturally, smoking should not be advocated as a means for reducing 
psychosocial symptoms, but should be recognized by clinicians a method of coping 
among women experiencing increases in vasomotor symptoms over time.  The 
recognition of this increase may lead the physician to treat the women with therapies 
which may reduce the hot flashes and in turn, lead to reduced depressive symptoms. 
 The results shown here on the association between vasomotor and psychosocial 
symptoms confirm what has been shown in the literature using a new and innovative 
way of categorizing both the exposure and outcome with the MENQOL.  Using the 
vasomotor and psychosocial domains for the exposure and outcome definitions, 
respectively, a broad categorization of various items was used to quantify a single 
concept.  This is an advantage over existing literature, which has used either a single 
dichotomous outcome, or more than one model to express the relationship between 
vasomotor symptoms and many psychological outcomes.   
 We have shown here that the MENQOL is an appropriate tool to use in a 
population-based sample, that is has good psychometric properties, and that it is well 
suited to study the relationship between hot flashes and depression over time.  However, 
it is also important to note that the population from which we derived this sample is 
appropriate to also draw such conclusions.  The Menopause Epidemiology Study and its 
follow up are well suited for such studies.  This study is a large, population-based study 
that is well representative of postmenopausal women in the United States aged 40-65 
years.   
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 Despite the conclusions this work may add to menopause literature, there are 
several limitations to the study conducted.  First, the factor analysis provides a wealth of 
knowledge to the field of menopause quality of life, but it was not possible to perform a 
true exploratory factor analysis using all 106 items originated in the initial instrument 
development.  There may have been other items which would have been suggested for 
retention via factor analysis that were excluded by investigators.  Second, the reliability 
coefficients were not as high as suggested by literature when the vaginal health items 
were added.  Though this does not mean that the items are not useful, it does mean that 
a few additional items, or potentially the re-wording of currently items, could help 
improve this reliability coefficient.   
 In the second analysis, it was necessary to restrict to only postmenopausal 
women, as this is the only population in which the MENQOL is validated.  Unfortunately, 
this precludes studying a highly variable time period during the menopausal period, the 
perimenopause, where changes in vasomotor symptoms are frequent and most 
bothersome.  We lose this sensitivity in restricting to studying a population that was not 
only post-menopause at baseline, but remains so two years later at follow-up, after the 
traditional peak of vasomotor symptoms have passed.  There also may exist a selection 
bias in the time between baseline and follow-up in that women whose psychosocial 
domain score had increased may have been less likely to participate, which would have 
driven our estimate toward the null.    Finally, there are a number of unmeasured 
confounders such as serotonin estrogen levels which could have a direct impact on 
either vasomotor symptoms or psychosocial symptoms which must be taken into 
consideration. 
 This is not to say that overall, the studies do not have their strengths.  The 
Menopause Epidemiology Study is a large, population-based study that is well 
representative of the United States.  The MENQOL is a validated instrument used to 
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measure quality of life and is able to capture not only the existence of frequent 
menopausal symptoms, but the degree of bother as well.  Additionally, the inclusion of 
supplemental vaginal health items is helpful to the instrument and will be able to provide 
physicians and researchers as well as patients the ability to explain their current 
symptom profile.  
 Also, the sensitivity analysis conducted on the second study enable us to be a 
little more confident in the relationship that change vasomotor symptoms have on 
changing psychosocial symptoms.  In looking at the relationship among those taking and 
not taking hormone therapy and depression medication, there were very similar results 
as the full model.  Furthermore, when it was found that tobacco use was a modifier, and 
that the outcome contained an anxiety component, we looked at a outcome 
encompassing depression only and found similar results.   
 In conclusion, we present an updated version of the Menopause-Specific Quality 
of Life Questionnaire, complete with a newly added Vaginal Health domain.  This 
research shows that these domains are fully sufficient to stand on their own, but may 
benefit from one or two additional vaginal health items to strengthen reliability. 
 Also, we show that an increase in vasomotor symptoms is associated with the 
increase in psychosocial symptoms over time.  Because this association was only 
quantified over two time points, true causality cannot be determined and further research 
is warranted and encouraged.  Meanwhile, it may be advantageous for clinicians to be 
aware of this association when treating women who are menopausal and reporting 
increasingly bothersome hot flashes over time.
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TABLES 














Age, years    
     40-44 24.8 848 (19.3) 255  (9.9) 
     45-49 23.4 900 (20.4) 465 (18.1) 
     50-54 20.0 920 (20.9) 544 (21.2) 
     55-59 16.5 827 (18.8) 508 (19.8) 
     60-67 15.3  907 (20.6)  791 (30.9) 
    
 
Race/Ethnicity 
   
     White, non-Hispanic 74.6 3,424 (77.8) 2,074 ( 80.9) 
     Black, non-Hispanic 11.8 497 (11.3) 248( 9.7) 
     Hispanic 4.5 150 (3.4) 80 (3.1) 
     Other, non-Hispanic 9.1 331 (7.5) 161 (6.3) 
    
 
Education 
   
     Less than high school 12.4 273 (6.2) 145 (5.7) 
     High school 33.7 1,721 (39.1) 948 (37.0) 
     Some college 27.7 1,265 (28.7) 746 (29.1) 
     Bachelor’s degree or higher 26.2 1,143( 26.0) 724 (28.3) 
*CPS: Current Population Survey,  2002.
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Table 2.  Distribution of domains from the MENQOL. 
Domain Item 
Vasomotor Hot Flashes 
 Night Sweats 
 Sweating 
  
Psychosocial Dissatisfaction of Personal Life 
 Feeling Anxious or Nervous 
 Poor Memory 
 Accomplishing less than I used to 
 Feeling down, depressed or blue 
 Being impatient with other people 
 Feelings of wanting to be alone 
  
Sexual  Change in sexual desire 
 Vaginal Dryness 
 Avoiding intimacy 
  
Physical Flatulence or gas pains 
 Aching muscles or joints 
 Feeling tired or worn out 
 Difficulty sleeping 
 Aches in back of neck or head 
 Decrease in physical strength 
 Decrease in stamina 
 Feeling a lack of energy 
 Drying skin 
 Weight gain 
 Increased facial hair 
 Changes in appearance, texture, or tone of skin 
 Feeling Bloated 
 Low backache 
 Frequent urination 
 Involuntary Urination 
 
Table 3. Additional Vaginal Health Characteristics appended to original MENQOL 
Instrument 
Vaginal Health Characteristic added to MENQOL 
Vaginal Irritation 
Vaginal Itching 
Pain, Difficulty, or Burning during Urination  
Vaginal Pain associated with sexual activity 




Table 4.  Original hypothesized factoring structure for appended vaginal health items. 
What could happen? Likelihood? Reasoning 
All 6 items load into their 
own ‘Vaginal Atrophy’ Factor 
Unlikely There are symptoms that appear to be 
more physical, and those that appear to 
be more sexual in nature. 
   
Items 1,2,3, and 6 load into 
the MENQOL Physical 
Functioning Domain; 4 and 
5 load into Sexual 
Functioning Doman 
Possible 1,2,3,4 and 7 have physical qualities;  5 
and 6 are associated with sexual activity 
   
Items 1,2,3, and 6 load into 
the MENQOL Physical 
Functioning Domain; 4 and 
5 do not load well into any 
MENQOL domain 
Possible 5 and 6 are somewhat abstract from the 
other MENQOL sexual functioning 
measures. 
   
All 6 items load into 
MENQOL Physical 
Functioning  Domain 
Possible The 6 additional items all have the 
potential for some physical functioning 
aspect. 
   
None of the 6 items are 
stable enough to load into 
factors 
Possible The addition of questions to a validated 
questionnaire may not support the 
inclusion of standalone factors. 
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Mean: 3.19 (1.75) 
51.66 (n=778) 
39.64 (n=597) 
8.70   (n=131) 
 






Income  0 = <$25,000 
1 = $25,000 – $74,000 






BMI† 0= <25 





missing = 64 
Deviates from 
traditional BMI 
cutpoints.  There 
were few (n=19) with 
BMI <18. 
Marital Status 0 = Currently Married 










1= 1-3 days a month 
2= 1-3 days a week 
3= 3-5 days a week 








Smoking 0 = Non-current smoker 











SERMS not included 






Table 5 (cont’d) 




Parity 0 = Never given birth 
1= 1 








0 = No 
1 = Current Depression  




Hysterectomy 0= No Hysterectomy 







Table 6.  Power estimates for main effects analyses using logistic regression. 
Odds Ratio Sample Size P (Vas inc among those 
with no change in psy 
domain) 
Power 
1.1 1,506 0.23 0.33 
1.2 1,506 0.23 0.83 
1.3 1,506 0.23 0.98 
1.4 1,506 0.23 1.00 
1.5 1,506 0.23 1.00 
1.6 1,506 0.23 1.00 
2.0 1,506 0.23 1.00 
2.1 1,506 0.23 1.00 
 
 























0.2 899 0.65 1.3 0.82 
0.4 899 0.65 1.3 0.99 
0.5 899 0.65 1.3 1.00 
0.75 899 0.65 1.3 1.00 
1.0 899 0.65 1.3 1.00 
1.25 899 0.65 1.3 1.00 
1.50 899 0.65 1.3 1.00 
2.0 899 0.65 1.3 1.00 
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Table 8.  Descriptive statistics of the MEPI study population. 
*  Current Population Survey.  US Census Bureau, 2002.
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Table 9.  Existing MENQOL, restricted to 4 factors, among postmenopausal women 40-
65 years old in the United States. 
Variable Factor Loading 
PHYSICAL  
     Aches in Muscles 0.739 
     Decrease in Physical Strength 0.735 
     Decrease in Stamina 0.687 
     Feeling a Lack of Energy 0.652 
     Low Backache 0.643 
     Feeling Tired or Worn Out    0.595 / 0.348* 
     Aches in back of Head or Neck 0.587 
     Feeling Bloated 0.543 
     Accomplishing Less than I Used To  0.4934 / 0.394* 
     Flatulence (Wind) or Gas Pains 0.493 
     Increased Facial Hair 0.421 
     Changes in Appearance, Texture or Tone of your Skin  0.344 / 0.245* 
     Weight Gain 0.496 
     Dry Skin 0.443 
     Involuntary Urination when Laughing  or Coughing 0.425 
     Frequent Urination 0.464 




     Down, Depressed, or Blue 0.866 
     Being Dissatisfied with my Personal Life 0.813 
     Feeling Anxious or Nervous 0.789 
     Feelings of Wanting to be Alone 0.699 
     Being Impatient with Other People 0.593 




     Hot Flashes 0.847 
     Night Sweats 0.841 




     Avoiding Intimacy 0.775 
     Decreased Sexual Desire 0.765 
     Vaginal Dryness 0.708 
* Crossloading 
† Classified the same as in the existing instrument
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Table 10.  Existing MENQOL, modified after dropping Accomplish, Memory, Sleeping, 
Tired, and Skin Tone, among postmenopausal women 40-65 years old in the United 
States. 
Variable Factor Loading 
PHYSICAL (ALPHA=0.86)  
     Aches in Muscles 0.747 
     Decrease in Physical Strength 0.737 
     Decrease in Stamina 0.680 
     Feeling a Lack of Energy 0.630 
     Low Backache 0.672 
     Aches in back of Head or Neck 0.620 
     Feeling Bloated 0.560 
     Flatulence (Wind) or Gas Pains 0.514 
     Increased Facial Hair 0.407 
     Weight Gain 0.495 
     Dry Skin 0.438 
     Involuntary Urination when Laughing or Coughing 0.444 




     Down, Depressed, or Blue 0.868 
     Being Dissatisfied with my Personal Life 0.823 
     Feeling Anxious or Nervous 0.786 
     Feelings of Wanting to be Alone 0.708 




     Hot Flashes 0.871 
     Night Sweats 0.859 
     Sweating 0.798 
 
SEXUAL* (ALPHA= 0.78) 
 
     Avoiding Intimacy 0.801 
     Decreased Sexual Desire 0.794 
     Vaginal Dryness 0.740 
* Domains classified the same as in the existing instrument 
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Table 11.  Inter-factor Correlations, Existing MENQOL, after Factor Analysis. 
 Physical Psychosocial Vasomotor Sexual 
Physical 1.00 0.53 0.33 0.34 
Psychosocial 0.53 1.00 0.29 0.33 
Vasomotor 0.33 0.29 1.00 0.23 
Sexual 0.34 0.33 0.23 1.00 
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Table 12.  Revised MENQOL, after removing Cross Loading Factors and Including 
Vaginal Health Items, among postmenopausal women 40-65 years old in the United 
States. 
Variable Factor Loading 
PHYSICAL  
   Decrease in Physical Strength 0.768 
   Decrease in Stamina 0.717 
   Aches in Muscles 0.728 
   Feeling a Lack of Energy 0.659 
   Low Backache 0.645 
   Aches in back of Head or Neck 0.606 
   Weight Gain 0.552 
   Flatulence Gas or Wind Pains 0.502 
   Increased Facial Hair 0.443 
   Feeling Bloated 0.567 
   Dry Skin 0.450 
   Involuntary Urination when Laughing or Coughing 0.465 




   Down, Depressed, or Blue 0.861 
   Being Dissatisfied with my Personal Life 0.821 
   Feeling Anxious or Nervous 0.785 
   Feelings of Wanting to be Alone 0.715 




   Vaginal Dryness 0.736 
   Vaginal Pain on Sex* 0.724 
   Avoiding Intimacy 0.732 
   Decreased Sexual Desire 0.718 




   Night Sweats 0.865 
   Hot Flashes 0.876 
   Sweating 0.799 
 
VAGINAL HEALTH  
 
   Vaginal Irritation* 0.731 
   Vaginal Itching* 0.726 
   Vaginal Pain Difficulty or Burning during Urination* 0.539 
   Vaginal Discharge* 0.569 
Note: To begin this analysis, we started with the 24 item MENQOL found in Phase I, 
eliminating Accomplish, Memory, Sleeping, Tired and Skin Tone from the original pool. 
* Added Vaginal Health items 
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Table 13.  Final Suggested Revised MENQOL, after removing Cross Loading Factors 
and Including Five Suggested Vaginal Health Items, among postmenopausal women 40-
65 years old in the United States. 
Variable Factor Loading 
Physical  (ALPHA =0.86)  
   Decrease in Physical Strength 0.768 
   Decrease in Stamina 0.717 
   Aches in Muscles 0.735 
   Feeling a Lack of Energy 0.657 
   Low Backache 0.652 
   Aches in back of Head or Neck 0.613 
   Weight Gain 0.542 
   Increased Facial Hair 0.440 
   Feeling Bloated 0.563 
   Dry Skin 0.443 
   Flatulence or wind Pains 0.496 
   Involuntary Urination when Laughing or  
   Coughing 
0.452 
   Frequent Urination 0.459 
PSYCHOSOCIAL (ALPHA=0.84)  
   Down, Depressed, or Blue 0.860 
   Being Dissatisfied with my Personal Life 0.821 
   Feeling Anxious or Nervous 0.784 
   Feelings of Wanting to be Alone 0.717 
   Being Impatient with Other People 0.601 
VAGINAL SEXUAL (ALPHA =0.77)  
   Vaginal Dryness 0.750 
   Vaginal Pain on Sex* 0.701 
   Avoiding Intimacy 0.756 
   Decreased Sexual Desire 0.742 
VASOMOTOR (ALPHA =0.86)  
   Night Sweats 0.866 
   Hot Flashes 0.877 
   Sweating 0.800 
VAGINAL HEALTH (ALPHA=0.67)  
   Vaginal Irritation* 0.754 
   Vaginal Itching* 0.748 
   Vaginal Pain Difficulty or Burning  
   during Urination* 
0.549 
   Vaginal Discharge* 0.569 
* Added vaginal health items. 
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Table 14.  Inter-factor Correlations for Phase II, Modified MENQOL 
 Physical Psychosocial Vasomotor Sexual Vaginal 
Health 
Physical 1.00 0.55 0.35 0.35 0.27 
Psychosocial 0.55 1.00 0.29 0.32 0.18 
Vasomotor 0.34 0.29 1.00 0.22 0.22 
Sexual 0.35 0.32 0.22 1.00 0.28 
Vaginal Health 0.27 0.18 0.22 0.28 1.00 
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Table 15.  Demographics of the MEPI Study Population. 
* United States Current Population Survey.  US Census Bureau, 2002. 
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Table 16.  Association Between Change in MENQOL* Vasomotor Domain Score and 
MENQOL Psychosocial Domain Score among Postmenopausal Women in the United 
States: Fully Adjusted Model (N=1,506). 
Parameter Mean Change in 
Psychosocial 
Score (SE) 
95% CI P-value 
Change in Vasomotor Score (1 unit change)    
   Current /Some Day Smoker 0.21 (0.04) (0.12, 0.29) <0.0001 
   Past /Never Smokers 0.29 (0.05) (0.20, 0.39) <0.0001 
Smoking    
   Past / Never Smoker  Ref.  0.10 
   Current /Some Day Smoker - 0.05 (0.03) (-0.11, 0.01) 
Change in Vasomotor Score *Smoking - 0.04 (0.02) (-0.07, 0.01) 0.02 
Baseline Vasomotor Score (1 unit change) 0.11 (0.02) (0.08, 0.15) <0.0001 
Hysterectomy/Oophorectomy    
   No Hysterectomy or Oophorectomy Ref.  0.22 
   Hysterectomy and/or oophorectomy - 0.10 (0.08) (-0.26, 0.06) 
Use of Hormone Therapy    
    No Ref.  0.32 
    Yes 0.08 (0.08) (-0.08, 0.25) 
Physical Activity    
  Never Ref.  
0.37 
  1 to 3 times a month 0.14 (0.10) (-0.06, 0.34) 
  1 to 3 times a week 0.18 (0.10) (-0.01, 0.38) 
  3 to 5 times a week 0.07 (0.10) (-0.13, 0.26) 
  6 to 7 times a week 0.13 (0.16) (-0.17, 0.44) 
Age (5 year change) - 0.09 (0.03) (-0.15, -0.02) 0.01 
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Table 16 (Cont’d) 






















Parameter Mean Change in 
Psychosocial 
Score (SE) 
95% CI P-value 
Married    
  Not Currently Married Ref.  0.71 
  Currently Married 0.03 (0.07) (-0.11, 0.17) 
Baseline Psychosocial Score (1 unit change) - 0.40 (0.02) (-0.44, -0.35) <0.0001 
Body Mass Index (1 unit change) 0.02 (0.01) (0.01, 0.03) <0.01 
Income Level    
   Less than $25,000 Ref.  
0.92    $25,000 - $74,999 0.01 (0.05) (-0.10, 0.11) 
   $75,000 and up 0.01 (0.11) (-0.20, 0.22) 
Race    
   White non-Hispanic Ref. - 0.53 
    Other 0.06 (0.09) (-0.12, 0.23) 
Parity    
   Never 0  
0.97    1  0.002 (0.04) (-0.07, 0.08) 
   2 or more 0.003 (0.08) (-0.15, 0.16) 
Years Since Menopause (5 year change) 0.01 (0.02) (-0.03, 0.06) 0.51 
Depression Medication    
  Not Currently Taking Ref.  0.01 
  Currently Taking 0.20 (0.08) (0.05, 0.35) 
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Table 17. Association Between Change in MENQOL* Vasomotor Domain Score and 
MENQOL Psychosocial Domain Score among Postmenopausal Subpopulations in the 
United States: Fully Adjusted Main Effects (N=1,506) 
* MENQOL:  Menopause-Specific Quality of Life Questionnaire 
**
 Adjusted for Baseline Vasomotor Score, Hysterectomy/Oophorectomy, Smoking Status, Physical 
Activity, Age, Marital Status, Baseline Psychosocial Status, Body Mass Index, Income, Race, Parity, and 
Years Since Menopause. 
†True effect modifiers.










Those on Hormone Therapy (N=298)    
Smokers: Change in Vasomotor Score 0.13 (0.09) (-0.06, 0.31) 0.17 
Non-smokers: Change in Vasomotor Score 0.14 (0.09) (-0.04, 0.33) 0.12 
Those not on Hormone Therapy (N=1,208)†    
Smokers: Change in Vasomotor Score 0.24 (0.02) (0.14, 0.33) <0.0001 
Non-smokers: Change in Vasomotor Score 0.34 (0.06) (0.23, 0.46) <0.0001 
Those on Depression Medication (N=415)    
Smokers: Change in Vasomotor Score 0.26 (0.08) (0.11, 0.41) <0.001 
Non-smokers: Change in Vasomotor Score 0.29 (0.08) (0.14, 0.44) <0.001 
Those not on Depression Medication (N=1,019)    
Smokers: Change in Vasomotor Score 0.17 (0.05) (0.07, 0.28) 0.001 
Non-smokers: Change in Vasomotor Score 0.26 (0.06) (0.14, 0.38) <0.0001 
Those not on Hormone Therapy or Depression 
Medication (N=840)† 
   
Smokers: Change in Vasomotor Score 0.23 (0.06) (0.12, 0.35) <0.0001 
Non-smokers: Change in Vasomotor Score 0.35 (0.07) (0.22, 0.49) <0.0001 
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Figure 2.  Enrollment of population of postmenopausal women from the Menopause 










































No consent to study 
(n=293) 


















Figure 3.  Scree plot example 
 
 
In the figure above, an ‘elbow’ can be seen at component number 3, suggesting that 2 
factors should be extracted from the data.  Figure source: 
http://janda.org/workshop/factor%20analysis/SPSS%20run/SPSS08.htm
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Appendix A2.  MENQOL Scoring 
 






I did not experience the problem in the 
last month. ‘No’ 1 
 
I did experience the problem, but it was 
not at all bothersome. ‘Yes’,  0 2 
 
I did experience the symptom, and 
marked bothersome as a ‘1’ ‘Yes’, 1 3 
 
I did experience the symptom, and 
marked bothersome as a ‘2’ ‘Yes’, 2 4 
 
I did experience the symptom, and 
marked bothersome as a ‘3’ ‘Yes’, 3 5 
 
I did experience the symptom, and 
marked bothersome as a ‘4’ ‘Yes’, 4 6 
 
I did experience the symptom, and 
marked bothersome as a ‘5’ ‘Yes’, 5 7 
 
I did experience the symptom, and 
marked bothersome as a ‘6’ ‘Yes’, 6 8 
Each item is rescaled and then items within domains are averaged. 
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Appendix A3. Methodological Considerations for Inclusion of Covariates 
 
 The ultimate goal for this analysis is to evaluate the extent to which depression is 
exacerbated (or initiated) by bothersome hot flashes.  To do so, several important 
confounders and effect modifiers must be considered. To date, many studies have 
attempted to examine associations between depression and hot flashes, but have 
skirted the epidemiologic issues that are inherent in conducting studies of association, 
namely, including crucial confounders in analysis.  The following sections detail 
covariates that will be available from the MEPI I and its followup study and that are 
important potential confounders for this analysis. 
Race.  Race and ethnicity may be potential confounders and/or effect modifiers, but 
have been understudied in the specific role they play in a study on depression and hot 
flashes.  Recent studies have shown that African American women are more likely than 
Caucasian women to experience hot flashes, due to differences found in estrogen levels 
and body mass index, even after controlling for differences in age and menopausal 
status (28, 102).  Additionally, it was found that African American and Hispanic 
menopausal women had some of the highest depression scores, compared to white, 
non-Hispanic women (103). 
Marital Status. The impact that marital status has on both vasomotor and psychosocial 
outcomes has been debated.  While some studies have shown that separated women 
have significantly high MENQOL scores for vasomotor and psychosocial domains (13), 
others have demonstrated that married women actually exhibit the most bothersome 
scores (14).  Given this inconsistency, and that both of these studies were performed in 
women of other countries, marital status is something that should be controlled for in the 
model, and should be done so with finer granularity than just “married vs non-married”.   
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Income.  Though these studies were performed in various countries, the prevalence of 
hot flashes among low income women supersedes that of higher income women (5, 23). 
Also, lower income levels are a risk factor for depression, which makes income a 
covariate that should be controlled for (104). 
Body Mass Index.  Obesity and increased body mass index is a risk factor for hot flashes 
(105).  Additionally, BMI was found to be associated not only with the existence of hot 
flashes, but increased frequency, and increase severity (30).   On the contrary, 
abdominal fat increases circulating estrogen and may actually reduce the frequency and 
intensity of hot flashes in obese women (21) Conversely, increased body mass index 
has been found to lower depressive symptoms, in post-menopausal women with lower 
education (106). These inconsistent finding provide support for the inclusion of body 
mass index in models.   
Smoking Status.  Smoking status is known to exacerbate hot flashes (28).  Additionally, 
smoking is associated with depression, but the true direction of causality is debated in 
literature (107).  Smoking status’ potential influence on both the exposure and outcome 
requires that it be included for adjustment as a confounder in the modeling algorithm. 
Physical Activity Levels.  The literature surrounding the association between hot flashes 
and physical activity is unclear.  Some studies have found a dose response relationship 
that demonstrated increased physical activity was helpful in reducing hot flashes (108).   
On the contrary, other studies have found that in general, physical activity levels are not 
associated with hot flashes, but may be associated with decreased hot flashes in women 
with a history of depression (108-109).  Given these contradictory results, it is possible 
that physical activity levels may modify the association between depression and hot 
flashes, and thus, must be included in analysis. 
Healthcare Seeking.  Women who are seeking care for their menopausal symptoms are 
likely to be prescribed medication, advice, and/or complementary medicine (110).  This 
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pattern of behavior may make women who seek healthcare different from women who 
do not seek this service or who have limited access to care.  The inclusion of this 
variable will prove valuable as a potential effect modifier or confounder. 
Hormone Therapies. The use of estrogen alone, or combined estrogen + progestin 
compounds were common for the relief of hot flashes (111).  This use was decreased 
substantially after initial reports of the potential cardiovascular threats that these 
compounds posed, and prescribing rates were greatly diminished (112).  However, it 
should be noted that the effect that these compounds have on hot flashes and 
depression makes controlling for hormone use imperative (113). 
Depression Medication.  Depression medication may be the biggest potential confounder 
of all listed here.  Depression medication, for the most obvious of reasons, is used to 
treat depression.  However, after the results of the Women Health Initiative, many 
women discontinued use of hormone replacement therapy, and that this decrease was 
correlated with an increased use of depression medication (114).  Since then, some 
studies have shown that depression medications such as escitalopram are more helpful 
than hormone therapy at reducing menopausal symptoms (115-116).  Other drugs such 
as venlafaxine and paroxetine have been effective at reducing hot flashes and 
depression, but are not without side effects (64-65, 117).  Other medications such as 
sertraline and fluoxetine have been shown to be not as effective (118). 
Prior Depression Diagnosis. A history of depression earlier in life is associated with the 
recurrence of depression during the menopausal transition (119).  Prior depression has 
also been associated with an increase in hot flashes (120).   
History of Breast Cancer.  Breast cancer is a likely confounder in this analysis due to its 
causal effects on both the exposure and the outcome. Breast cancer is likely to occur 
around the same time as the menopausal transition. Breast cancer patients often report 
hot flashes; this quality of life issue is only exacerbated when estrogenic compounds are 
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contraindicated and cannot be used for treatment (121).  Breast cancer is also a known 
cause of depression, especially in the absence of family support (122). 
Parity.  Parity may play a role of a confounder in this proposed association, but literature 
is conflicting.  In a small sample of Ecuadorian women a parity of four children or greater 
were associated with increased number of hot flashes (123).  Likewise, post-partum 
depression is associated with parity and is likely to contribute to the association of parity 
with depression, though causal mechanisms are unclear (52). 
Hysterectomy and/or Oophorectomy.  The removal of a woman’s uterus and, more 
specifically, ovaries causes the onset of surgical menopause (24).  This procedure will 
produce hot flashes in the same manner as would a natural menopause.  It has been 
suggested that a hysterectomy would also cause feelings of depression; if so, this is an 
important potential confounder which would need to be controlled for in analysis (124). 
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Appendix A6.  Association Between Change in MENQOL* Vasomotor Domain Score and 
MENQOL “Feeling Down, Depressed, or Blue” Score among Postmenopausal 
Subpopulations in the United States: Fully Adjusted Main Effects (N=1,506) 
 
Parameter Mean Change in 
Psychosocial Score (SE) 
P-value 
Change in Vasomotor Score    0.20 (0.04) <0.0001 
Baseline Vasomotor Score    0.17 (0.03) <0.0001 
Hysterectomy/Oophorectomy - 0.08 (0.14) 0.54 
Smoking - 0.08 (0.05) 0.09 
Physical Activity   




  1 to 3 times a month   0.22 (0.17) 
  1 to 3 times a week   0.40 (0.17) 
  3 to 5 times a week   0.24 (0.16) 
  6 to 7 times a week   0.06 (0.26) 
Age (5 year change) -0.13 (0.06) 0.02 
Married   0.12 (0.12) 0.32 
Baseline Psychosocial Score - 0.62 (0.02)   <0.0001 
Body Mass Index   0.02 (0.01) 0.02 
Income Level   
   Less than $25,000 0 0.99 
   $25,000 - $74,999 0.01 (0.09) 
   $75,000 and up 0.01 (0.18) 
Other Race (vs White) - 0.07 (0.15) 0.62 
Parity   
   Never 0 0.07 
   1    0.11 (0.06) 
   2 or more   0.23 (0.13) 
Years Since Menopause (5 
year change) 
  0.04 (0.04) 0.34 
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